Skytrofa Injection, Powder, Lyophilized, For Solution
FDA Label NDC 73362-005

58 label sections · Submitted to the FDA by Ascendis Pharma Endocrinology, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Ascendis Pharma Endocrinology, Inc. for the product Skytrofa (NDC 73362-005). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 general dosing information, 2.2 recommended dosage for pediatric patients, 2.3 recommended dosage for adults, 2.4 missed doses, 2.5 administration instructions for pediatric patients, 2.6 administration instructions for adults, 2.7 preparation and administration, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

1 Indications And Usage

SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the:

  • Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).
  • Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).

2.1 General Dosing Information

  • For subcutaneous injection, once weekly.
  • Therapy with SKYTROFA should be supervised by a healthcare provider who is experienced in the diagnosis and management of patients with growth hormone deficiency (GHD).
  • Perform fundoscopic examination before initiating treatment with SKYTROFA to exclude preexisting papilledema. If papilledema is identified, evaluate the etiology and treat the underlying cause before initiating treatment with SKYTROFA [see Warnings and Precautions (5.5)].

2.2 Recommended Dosage For Pediatric Patients

  • The recommended dose of SKYTROFA for treatment-naïve patients and patients switching from another growth hormone product is 0.24 mg/kg body weight, given once weekly.
  • Individualize and titrate the dosage of SKYTROFA based on response.
  • When changing from daily somatropin therapy to once-weekly SKYTROFA, wait at least 8 hours between the final dose of daily somatropin and the first dose of SKYTROFA.
  • When changing from another once-weekly growth hormone therapy to once-weekly SKYTROFA, wait at least 7 days between the final dose of the previous growth hormone therapy and the first dose of SKYTROFA.
  • Assess compliance and evaluate other causes of poor growth, such as hypothyroidism, under-nutrition, advanced bone age and antibodies to recombinant human growth hormone if patients experience failure to increase height velocity, particularly during the first year of treatment.
  • Patients who were treated with SKYTROFA for GH deficiency in childhood and whose epiphyses are closed should be reevaluated before continuing SKYTROFA.

2.3 Recommended Dosage For Adults

  • The recommended starting dose of SKYTROFA in adults with GHD is based on age and concomitant use of oral estrogen [see Dosage Forms and Strengths (3)]. For treatment-naïve patients or for patients switching from another growth hormone product, start SKYTROFA as described below:
    • 1.4 mg once weekly for adults 30 to 60 years old, with no oral estrogen intake
    • 2.1 mg once weekly for adults under 30 years old, or adults of any age intaking oral estrogen
    • 0.7 mg once weekly for adults over 60 years old, with no oral estrogen intake
    • When changing from daily somatropin therapy to once-weekly SKYTROFA, wait at least 8 hours between the final dose of daily somatropin and the first dose of SKYTROFA.
    • When changing from another once-weekly growth hormone therapy to once-weekly SKYTROFA, wait at least 7 days between the final dose of the previous growth hormone therapy and the first dose of SKYTROFA.
    • Increase the dose monthly to a higher strength cartridge based on the clinical response and/or IGF-1 concentration. Draw IGF-1 serum sample 4 to 5 days after the prior dose.
    • Decrease the dose to a lower strength cartridge as needed based on adverse reactions or a weekly average IGF-1 concentration above the age- and sex-specific normal range.
    • The maximum recommended dose is 6.3 mg once weekly.

2.4 Missed Doses

  • Administer a missed dose as soon as possible and not more than 2 days after the missed dose.
  • To avoid missed doses, SKYTROFA can be taken 2 days before or 2 days after the scheduled dosing day. Resume once-weekly dosing for the next dose at the previously scheduled dosing day.
  • If more than 2 days have passed from the scheduled day, skip the dose and administer the next dose on the regularly scheduled day.
  • At least 5 days should elapse between doses.

2.5 Administration Instructions For Pediatric Patients

SKYTROFA is available in 9 cartridges (dosage strengths in somatropin equivalents) for pediatric patients.

Selection of the appropriate cartridge (mg) is based on the prescribed dose (mg/kg) and the patient's body weight (kg) [see Dosage Forms and Strengths (3)].

  • If prescribing a dose of 0.24 mg/kg/week and the patient's weight is 11.5 to 100 kg, follow the recommended dosing in Table 1.
  • If prescribing a dose other than 0.24 mg/kg/week, calculate the total weekly dose (in mg) and select the appropriate cartridge as follows:
    • Total weekly dose (mg) = prescribed weekly dose (mg/kg) × patient's body weight (kg).
    • Round the total weekly dose (mg) to the closest cartridge dose while also considering treatment goals and clinical response.
    • Table 1: Recommended Dosing for Pediatric Patients Prescribed Doses of 0.24 mg/kg/week
      Weight (kg)Dose (mg)
      11.5 – 13.93
      14 – 16.43.6
      16.5 – 19.94.3
      20 – 23.95.2
      24 – 28.96.3
      29 – 34.97.6
      35 – 41.99.1
      42 – 50.911
      51 – 60.413.3
      60.5 – 69.915.2 (using two cartridges of 7.6 mg each)
      70 – 84.918.2 (using two cartridges of 9.1 mg each)
      85 – 10022 (using two cartridges of 11 mg each)

2.6 Administration Instructions For Adults

SKYTROFA is available in 14 cartridges (dosage strengths in somatropin equivalents) for adults.

Selection of the appropriate cartridge (mg) is based on the prescribed dose (mg/week) [see Dosage Forms and Strengths (3)].

2.7 Preparation And Administration

  • The SKYTROFA cartridge has been designed for use only with the SKYTROFA Auto-Injector.
  • If refrigerated, the SKYTROFA cartridge must be kept at room temperature for 15 minutes before use.
  • The SKYTROFA Auto-Injector provides a fully automated reconstitution of the lyophilized drug product which is followed by a manual mixing step controlled by the device. When the injection needle is inserted into the skin, the device automatically delivers the drug product. The built-in electronics and software assist the user during the entire preparation and injection sequence and provide confirmation that the full dose has been delivered.
  • The mixed solution should be clear and colorless to opalescent. The solution may contain air bubbles and this is acceptable. DO NOT inject if the solution is cloudy or contains particulate matter.
  • Use SKYTROFA cartridges within 4 hours after reconstitution. Discard reconstituted SKYTROFA cartridges after 4 hours when stored at room temperature up to 86°F (30°C).
  • Inject SKYTROFA subcutaneously into the abdomen, buttock, or thigh. Rotate injection sites between and within regions to reduce the risk of lipoatrophy [see Warnings and Precautions (5.12)].
  • Refer to the Instructions for Use for complete administration instructions with illustrations. The instructions can also be found on www.Skytrofa.com/IFU.
  • Patients and/or caregivers who will administer SKYTROFA should receive appropriate training and instruction on the proper use of SKYTROFA from their healthcare provider.

3 Dosage Forms And Strengths

SKYTROFA is a white to off-white lyophilized powder available in a single-dose, dual-chamber, prefilled cartridge containing lonapegsomatropin-tcgd in one chamber and diluent, Water for Injection, in the other chamber and is available in the following strengths:

For injection: 0.7 mg, 1.4 mg, 1.8 mg, 2.1 mg, 2.5 mg, 3 mg, 3.6 mg, 4.3 mg, 5.2 mg, 6.3 mg, 7.6 mg, 9.1 mg, 11 mg, and 13.3 mg.

4 Contraindications

SKYTROFA is contraindicated in patients with:

  • Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin [see Warnings and Precautions (5.1)].
  • Hypersensitivity to somatropin or any of the excipients in SKYTROFA. Severe systemic hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported [see Warnings and Precautions (5.2)].
  • Pediatric patients with closed epiphyses.
  • Active malignancy due to the risk of malignancy progression [see Warnings and Precautions (5.3)].
  • Active proliferative or severe non-proliferative diabetic retinopathy because treatment with somatropin may worsen this condition.
  • Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to the risk of sudden death [see Warnings and Precautions (5.13)].

5.1 Increased Mortality In Patients With Acute Critical Illness

Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic doses of somatropin [see Contraindications (4)].

The safety of continuing SKYTROFA treatment in patients receiving replacement doses for the approved indication who concurrently develop these illnesses has not been established.

5.2 Severe Hypersensitivity

Severe systemic hypersensitivity reactions, including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products, including SKYTROFA. Inform patients and/or caregivers that such reactions are possible, and that prompt medical attention should be sought if an allergic reaction occurs. SKYTROFA is contraindicated in patients with known hypersensitivity to somatropin or any of the excipients in SKYTROFA.

Other

Active Malignancy

There is an increased risk of malignancy progression with somatropin treatment in patients with active malignancy [see Contraindications (4)]. Any preexisting malignancy should be inactive, and its treatment should be completed prior to instituting therapy with SKYTROFA. Discontinue SKYTROFA if there is evidence of recurrent malignancy.

New Malignancy During Treatment

Because children with certain rare genetic causes of short stature have an increased risk of developing malignancies, thoroughly consider the risks and benefits of starting somatropin in these patients. If treatment with somatropin is initiated, carefully monitor these patients for development of neoplasms.

Monitor patients on SKYTROFA therapy carefully for increased growth or potential malignant changes of preexisting nevi. Advise patients/caregivers to report marked changes in behavior, onset of headaches, vision disturbances and/or changes in skin pigmentation or changes in the appearance of preexisting nevi.

Pediatric Patients with Growth Hormone Deficiency

SKYTROFA was studied in a 52-week, open-label, active-controlled trial in 161 treatment-naïve, prepubertal pediatric patients with growth hormone deficiency (GHD) [see Clinical Studies (14.1)]. The subjects ranged in age from 3.2 to 13.1 years with a mean of 8.5 years. One hundred thirty-two (82%) of the subjects were male and 29 (18%) were female. One subject was Asian, 3 were Black or African American, 152 were Caucasian, and 5 were categorized as "other."

Table 2 shows common adverse reactions that occurred in ≥ 5% of patients treated with SKYTROFA in this trial.

Table 2: Adverse Reactions Occurring in ≥ 5% SKYTROFA-Treated Pediatric Patients and More Frequently Than in Daily Somatropin-Treated Pediatric Patients (52 Weeks of Treatment)
Adverse reactionsDaily Somatropin
(N = 56)
n (%)
SKYTROFA
(N = 105)
n (%)
Adverse reactions that are medically related were grouped to a single preferred term.
Infection, viral6 (11%)16 (15%)
Pyrexia5 (9%)16 (15%)
Cough4 (7%)11 (11%)
Nausea and vomiting4 (7%)11 (11%)
Hemorrhage

Hemorrhage in the SKYTROFA treatment group included epistaxis (3), contusion (2), petechiae (1) and eye hemorrhage (1).

1 (2%)7 (7%)
Diarrhea3 (5%)6 (6%)
Abdominal pain2 (4%)6 (6%)
Arthralgia and arthritis

Arthralgia and arthritis in the SKYTROFA treatment group included arthralgia (5) and reactive arthritis (1).

1 (2%)6 (6%)

Laboratory Tests

More SKYTROFA-treated patients shifted from normal baseline levels to elevated phosphate and alkaline phosphatase levels at the end of the trial compared to the daily somatropin group (44.2% vs. 30.2% and 19.2% vs. 9.4%, respectively); these laboratory changes occurred intermittently [see Warnings and Precautions (5.14)].

Adults with Growth Hormone Deficiency

SKYTROFA was studied in a 38-week parallel-arm, placebo-controlled (double-blind) and active-controlled (open label) trial in 259 adults with growth hormone deficiency (GHD) [see Clinical Studies (14.2)].

The mean (range) age at enrollment was 43 (23 to 81) years old, with 119 (46%) females (55 on oral estrogen) and 140 (54%) males. One subject was American Indian or Alaska Native, one was Black or African American, 28 were Asian, and 218 were Caucasian.

Table 3 shows adverse reactions that occurred in ≥ 5% of adults treated with SKYTROFA and more frequently than in placebo-treated adults in this trial.

Table 3: Adverse Reactions Occurring in ≥ 5% of SKYTROFA-Treated Adults and More Frequently Than in Placebo-treated Adults (38 Weeks of Treatment)
Adverse reactionsPlacebo
(N = 84)
n (%)
SKYTROFA
(N = 89)
n (%)
Adverse reactions that are medically related were grouped to a single preferred term.
Edema

Edema in the SKYTROFA treatment group included edema peripheral (6) and peripheral swelling (1).

1 (1%)7 (8%)
Central (secondary) hypothyroidism

Central (secondary) hypothyroidism in the SKYTROFA treatment group included thyroxine free decreased (3), central hypothyroidism (2), thyroxine decreased (1), blood thyroid stimulating hormone decreased (1), tri-iodothyronine free decreased (1). Preexisting central hypothyroidism in 5 of 6 SKYTROFA-treated patients.

1 (1%)6 (7%)

Laboratory Tests

More SKYTROFA-treated patients shifted from normal or low baseline levels to elevated alkaline phosphatase levels at the end of the trial compared to the placebo group (14% vs. 6%); these laboratory changes were noted with increased frequency as the trial progressed [see Warnings and Precautions (5.14)].

Risk Summary

There are no available data on lonapegsomatropin-tcgd use in pregnant patients to evaluate a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Available published data over several decades for somatropin, the active component of lonapegsomatropin-tcgd, have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, there was no evidence of embryo-fetal or neonatal harm when pregnant rats were administered subcutaneous lonapegsomatropin-tcgd at doses up to 13-fold the clinical pediatric dose of 0.24 mg/kg/week and approximately 30-fold the maximum clinical therapeutic dose for adult GHD of 6.3 mg hGH/week (see Data).

The estimated background risk of birth defects and miscarriages for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

No embryonic or fetal development toxicities occurred in rats administered subcutaneous lonapegsomatropin-tcgd at doses up to 13-fold the clinical pediatric dose of 0.24 mg/kg/week and approximately 30-fold the maximum clinical therapeutic dose for adult GHD of 6.3 mg hGH/week.

In a peri- and post-natal developmental study in rats, there were no adverse effects on the pregnant/lactating female or on development of the conceptus and the offspring following exposure of the female from implantation through weaning to doses of a structurally related pegylated somatropin prodrug up to 13-fold the clinical pediatric dose of 0.24 mg/kg/week and approximately 30-fold the maximum clinical therapeutic dose for adult GHD of 6.3 mg hGH/week.

Risk Summary

There are no data on the presence of lonapegsomatropin-tcgd in human milk, effects on the breastfed infant, or effects on milk production. High molecular weight therapeutic proteins, including lonapegsomatropin-tcgd, are expected to have low passage into human milk and limited systemic exposure in the breastfed infant. Additionally, published data indicate that exogenous somatropin does not increase normal human milk concentrations of growth hormone. No adverse effects on the breastfed infant have been reported with somatropin. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SKYTROFA and any potential adverse effects on the breastfed infant from SKYTROFA or from the underlying maternal condition.

Absorption

Following subcutaneous dose administration, SKYTROFA releases fully active somatropin via autocleavage of the TransCon linker that follows first-order kinetics.

In pediatric patients with GHD, following subcutaneous dose administration of 0.24 mg/kg/week SKYTROFA, the observed mean (CV%) steady-state peak serum concentration (Cmax) of lonapegsomatropin-tcgd was 1230 (86.3) ng hGH/mL, and the median time to reach maximum concentrations (Tmax) was 25 hours. For released somatropin, Cmax was 15.2 (83.4) ng/mL with a median Tmax of 12 hours. The mean (CV%) somatropin exposure over the one-week dose interval (area under the curve) was 500 (83.8) h*ng/mL. Following subcutaneous dose administration of 0.24 mg/kg/week SKYTROFA, mean Cmax (CV%) of the methoxypolyethylene glycol carrier was 13.1 (28.1) mcg/mL with a median Tmax of 36 hours.

In adult patients with GHD, following subcutaneous administration of 6.3 mg/week SKYTROFA, the estimated median steady-state Cmax of lonapegsomatropin-tcgd was 69.3 ng hGH/mL, and the Tmax was 31 hours. For released somatropin, the estimated median Cmax was 2.47 ng/mL with a median Tmax of 13 hours. The median somatropin exposure over the one-week dose interval (area under the curve) was 75.4 h*ng/mL. Following subcutaneous dose administration of 6.3 mg/week SKYTROFA, the estimated median Cmax of the methoxypolyethylene glycol carrier was 4.60 mcg/mL with a median Tmax of 34 hours.

No significant accumulation of lonapegsomatropin-tcgd and somatropin following repeat dose administration was observed.

Distribution

In pediatric patients with GHD, the mean (CV%) steady-state apparent volume of distribution of lonapegsomatropin-tcgd after subcutaneous administration of 0.24 mg/kg/week SKYTROFA was 0.13 (109) L/kg.

In adult patients with GHD, the median steady-state apparent volume of distribution of lonapegsomatropin-tcgd after subcutaneous administration of 6.3 mg/week SKYTROFA was 0.13 L/kg.

A similar distribution pattern as observed for daily somatropin is expected once somatropin is released from lonapegsomatropin-tcgd.

Elimination

Metabolism

The metabolism of somatropin involves protein catabolism in both the liver and kidneys. The methoxypolyethylene glycol carrier is cleared by the kidneys.

Excretion

In pediatric patients with GHD, the mean (CV%) lonapegsomatropin-tcgd apparent clearance at steady state was 3.2 (67) mL/h/kg following subcutaneous administration of 0.24 mg/kg/week SKYTROFA with a mean (±SD) observed half-life of 30.7 (±12.7) hours.

The apparent half-life of somatropin released from lonapegsomatropin-tcgd was approximately 25 hours.

Specific Populations

Based on a population pharmacokinetic analysis, age (3.0 to 13.7 years for pediatric patients and 23 to 75 years for adult patients), sex, race, and body weight do not have clinically meaningful effects on pharmacokinetics.

Male and Female Patients — No sex-specific pharmacokinetic studies have been performed with SKYTROFA. The available literature indicates that the pharmacokinetics of somatropin are similar in men and women.

Patients with Renal or Hepatic Impairment — No specific studies have been performed with SKYTROFA.

How Supplied

SKYTROFA (lonapegsomatropin-tcgd) for injection is a sterile, preservative-free, white to off-white lyophilized powder available in a single-dose, dual-chamber, prefilled cartridge containing lonapegsomatropin-tcgd in one chamber and the diluent, Water for Injection, in the second chamber. The dual-chamber glass cartridge is available in 14 strengths (in somatropin equivalents) as described in Table 9.

Table 9: SKYTROFA Presentations
SKYTROFANDC
0.7 mg73362-012-01
1.4 mg73362-013-01
1.8 mg73362-014-01
2.1 mg73362-015-01
2.5 mg73362-016-01
3 mg73362-003-01
3.6 mg73362-004-01
4.3 mg73362-005-01
5.2 mg73362-006-01
6.3 mg73362-007-01
7.6 mg73362-008-01
9.1 mg73362-009-01
11 mg73362-010-01
13.3 mg73362-011-01

Each carton contains 4 single-dose prefilled cartridges and 6 sterile, single-use, disposable 0.25 mm × 4 mm (31-gauge × 5/32 inch) needles. The cartridges are for use only with the SKYTROFA Auto-Injector, packaged in a separate carton. The SKYTROFA Auto-Injector is not supplied with SKYTROFA cartridges but is available for patients with a prescription for SKYTROFA through the Ascendis Pharma Customer Support by calling the toll-free number at 1-844-442-7236 (1-844-44ASCENDIS).

Administration Instructions

  • Advise patients and/or caregivers to read the accompanying FDA-approved patient labeling SKYTROFA Auto-Injector Instructions for Use (also available at www.Skytrofa.com/IFU) prior to administration. Advise patients and/or caregivers to call the Ascendis Pharma Customer Support toll-free number at 1-844-442-7236 (1-844-44ASCENDIS) for assistance or additional training, if needed.
  • Advise patients and/or caregivers to refer to the Instructions for Use that accompanies the SKYTROFA Auto-Injector for complete mixing and administration instructions with illustrations [see Dosage and Administration (2.7)]. Instruct patients and/or caregivers of proper needle disposal and caution against any reuse of needles. An appropriate container for the disposal of used cartridge and needle should be used.
  • Advise patients and/or caregivers to administer SKYTROFA once weekly, at any time of day. Advise patients and/or caregivers that doses can be taken 2 days before or 2 days after the scheduled dosing day. Advise patients and/or caregivers to resume once-weekly dosing for the next dose. If more than 2 days have passed from the schedule dosing day, advise patients and/or caregivers to skip the missed dose and take the next dose on the regularly scheduled day. If subsequently changing the regular dosing day to a different day of the week, advise patients and/or caregivers to ensure that at least 5 days will elapse between the last dose and the newly established regular dosing day.
  • Hypersensitivity Reactions

    Advise patients and/or caregivers that severe and/or serious systemic hypersensitivity reactions (anaphylaxis and angioedema) have been reported, and to seek prompt medical attention should an allergic reaction occur [see Warnings and Precautions (5.2)].

    Neoplasms

    Advise childhood cancer survivors and/or caregivers that individuals treated with brain and/or head radiation are at increased risk of secondary neoplasms and, as a precaution, need to be monitored for recurrence. Advise patients and/or caregivers to report marked changes in behavior, onset of headaches, vision disturbances and/or changes in skin pigmentation or changes in the appearance of preexisting nevi.

    Glucose Intolerance/Diabetes Mellitus

    Advise patients and/or caregivers that new onset impaired glucose intolerance/type 2 diabetes mellitus or exacerbation of preexisting diabetes mellitus can occur and monitoring of blood glucose during treatment with SKYTROFA may be needed.

    Intracranial Hypertension

    Advise patients and/or caregivers to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting.

    Fluid Retention

    Advise patients and/or caregivers that fluid retention during SKYTROFA replacement therapy may occur. Inform patients and/or caregivers of the clinical manifestations of fluid retention (e.g., edema, arthralgia, myalgia, nerve compression syndromes, including carpal tunnel syndrome/paresthesia) and to report to their healthcare provider if any of these signs or symptoms occur during treatment with SKYTROFA.

    Hypoadrenalism

    Advise patients and/or caregivers that patients who have or who are at risk for pituitary hormone deficiency(s) that hypoadrenalism may develop and to report to their healthcare provider if they experience hyperpigmentation, extreme fatigue, dizziness, weakness, or weight loss.

    Hypothyroidism

    Advise patients and/or caregivers that undiagnosed/untreated hypothyroidism may prevent an optimal response to SKYTROFA. Advise patients/caregivers that patients may require periodic thyroid function tests.

    Pancreatitis

    Advise patients and/or caregivers that pancreatitis may develop and to report to their healthcare provider any new onset abdominal pain.

    © 2024 Ascendis Pharma. All rights reserved. SKYTROFA®, Ascendis®, TransCon®, the Ascendis Pharma logo and the company logo are trademarks owned by the Ascendis Pharma Group.

    PATENT INFORMATION: www.ascendispharma.us/products/patents

    Manufactured by:
    Ascendis Pharma Endocrinology Division A/S
    Tuborg Boulevard 12 Hellerup Denmark DK-2900
    U.S. License Number 2165

    For information about SKYTROFA contact:
    Ascendis Pharma Endocrinology, Inc.
    Princeton, New Jersey 08540, USA
    1-844-442-7236 (1-844-44ASCENDIS)
    www.Skytrofa.com

5.4 Glucose Intolerance And Diabetes Mellitus

Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. Previously undiagnosed impaired glucose tolerance and overt type 2 diabetes mellitus may be unmasked. Monitor glucose levels in all patients receiving SKYTROFA, especially in those with risk factors for type 2 diabetes mellitus, such as obesity or a family history of type 2 diabetes mellitus. When initiating SKYTROFA, monitor closely patients with preexisting type 1 or type 2 diabetes mellitus or impaired glucose tolerance and adjust the doses of antihyperglycemic drugs as needed.

5.5 Intracranial Hypertension

Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with somatropin. Symptoms usually occurred within 8 weeks after the initiation of somatropin. In all reported cases, IH-associated signs and symptoms resolved rapidly after cessation of therapy or a reduction of the somatropin dose. To exclude preexisting papilledema, perform fundoscopic examination before initiating treatment with SKYTROFA, and reassess periodically thereafter. If papilledema is observed by fundoscopy, stop somatropin treatment. If somatropin-induced IH is confirmed, restart treatment with SKYTROFA at a lower dose after IH-associated signs and symptoms have resolved.

5.6 Fluid Retention

Fluid retention during somatropin therapy may occur. Clinical manifestations of fluid retention (e.g., edema, arthralgia, myalgia, nerve compression syndromes, including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent.

5.7 Hypoadrenalism

Patients receiving somatropin therapy who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA therapy. Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in patients with known hypoadrenalism [see Drug Interactions (7)].

5.8 Hypothyroidism

Undiagnosed or untreated hypothyroidism may prevent optimal response to SKYTROFA. In patients with GHD, central (secondary) hypothyroidism may first become evident or worsen during SKYTROFA treatment. Therefore, perform periodic thyroid function tests in patients and initiate or appropriately adjust thyroid hormone replacement therapy when indicated.

5.9 Slipped Capital Femoral Epiphysis In Pediatric Patients

Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Slipped capital femoral epiphysis may lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients receiving SKYTROFA with the onset of a limp or complaints of persistent hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly.

5.10 Progression Of Preexisting Scoliosis In Pediatric Patients

Somatropin increases growth rate in pediatric patients, and progression of existing scoliosis can occur in patients who experience rapid growth. Somatropin has not been shown to increase the occurrence of scoliosis. Monitor patients with a history of scoliosis for disease progression.

5.11 Pancreatitis

Pancreatitis has been reported in pediatric patients receiving somatropin. The risk may be greater in pediatric patients than adults. Consider pancreatitis in patients who develop persistent severe abdominal pain.

5.12 Lipoatrophy

When SKYTROFA is administered subcutaneously at the same site over a long period of time, lipoatrophy may result. Rotate injection sites when administering SKYTROFA to reduce this risk [see Dosage and Administration (2.7)].

5.13 Sudden Death In Pediatric Patients With Prader-Willi Syndrome

There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. SKYTROFA is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.

5.14 Laboratory Tests

Serum levels of alkaline phosphatase and phosphate may increase after SKYTROFA therapy. Serum levels of parathyroid hormone may increase after somatropin treatment. If a patient is found to have abnormal laboratory tests, monitor as appropriate.

6 Adverse Reactions

The following important adverse reactions are described elsewhere in the labeling:

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of somatropin products or SKYTROFA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Severe systemic hypersensitivity reactions, including anaphylactic reactions and angioedema
  • Musculoskeletal and connective tissue disorders – osteonecrosis in pediatric patients

7 Drug Interactions

Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them.

Table 4: Clinically Important Drug Interactions with SKYTROFA
Replacement Glucocorticoid Treatment
Clinical Impact:Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11βHSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11βHSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations.
Intervention:Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA [see Warnings and Precautions (5.7)]
ExamplesCortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.
Pharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment
Clinical Impact:Pharmacologic glucocorticoid therapy and supraphysiologic glucocorticoid treatment may attenuate the growth-promoting effects of SKYTROFA in pediatric patients.
Intervention:Carefully adjust glucocorticoid replacement dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth.
Cytochrome P450-Metabolized Drugs
Clinical Impact:Limited published data indicate that somatropin treatment increases cytochrome P450 (CYP450)-mediated antipyrine clearance. SKYTROFA may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes.
Intervention:Careful monitoring is advisable when SKYTROFA is administered in combination with drugs metabolized by CYP450 liver enzymes.
Oral Estrogen
Clinical Impact:Oral estrogens may reduce the serum insulin-like growth factor-1 (IGF-1) response to SKYTROFA.
Intervention:Patients receiving oral estrogen replacement may require higher SKYTROFA dosages.
Insulin and/or Other Antihyperglycemic Agents
Clinical Impact:Treatment with SKYTROFA may decrease insulin sensitivity, particularly at higher doses.
Intervention:Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents [see Warnings and Precautions (5.4)].

8.4 Pediatric Use

Safety and effectiveness of SKYTROFA have been established in pediatric patients 1 year and older and who weigh at least 11.5 kg. Pediatric use was established in a controlled study of 161 treatment-naïve pediatric patients ages 3 to 13 years and by supportive data in pediatric patients 1 year and older [see Adverse Reactions (6) and Clinical Studies (14)].

The safety and effectiveness of SKYTROFA in children less than 1 year of age have not been established.

Use of somatropin in pediatric patients with Prader-Willi syndrome has been associated with reports of sudden death. SKYTROFA is not indicated for the treatment of pediatric patients with growth failure due to genetically confirmed Prader-Willi syndrome [see Warnings and Precautions (5.13)].

8.5 Geriatric Use

Of the 249 patients who received SKYTROFA in clinical studies, 24 (10%) patients were 65 years of age and older, and 4 (2%) patients were 75 years of age and older. Geriatric patients may be at an increased risk for adverse reactions. Initiate SKYTROFA at 0.7 mg once weekly in patients 60 years of age and older, not on estrogen therapy [see Dosage and Administration (2.3)].

9.1 Controlled Substance

SKYTROFA is a prodrug of somatropin. Somatropin is not a controlled substance.

9.2 Abuse

Inappropriate use of somatropin may result in significant negative health consequences.

9.3 Dependence

Somatropin is not associated with drug related withdrawal adverse reactions.

10 Overdosage

Acute overdosage may lead initially to hypoglycemia and subsequently to hyperglycemia. Overdose with somatropin may cause fluid retention. Long-term overdosage may result in signs and symptoms of gigantism consistent with the known effects of excess growth hormone.

11 Description

Lonapegsomatropin-tcgd is a long-acting prodrug of a human growth hormone (somatropin) produced by recombinant DNA technology using E. coli. Lonapegsomatropin-tcgd consists of a parent drug, somatropin, that is conjugated to a methoxypolyethylene glycol carrier (4 × 10 kDa mPEG) via a proprietary TransCon Linker and has a molecular weight of 63 kDa (released somatropin is 22 kDa). In vitro assay confirms the minimum potency of released somatropin is NLT 2.5 IU/mg.

SKYTROFA (lonapegsomatropin-tcgd) for injection is a sterile, preservative-free, white to off-white lyophilized powder available in a single-dose, dual-chamber, prefilled cartridge containing lonapegsomatropin-tcgd in one chamber and the diluent, Water for Injection, in the other chamber. SKYTROFA prefilled cartridge must be used with SKYTROFA Auto-Injector to provide an automatic mixing step for reconstitution prior to subcutaneous use.

After reconstitution, each prefilled cartridge delivers:

  • 0.327 mL containing 0.7 mg lonapegsomatropin-tcgd, succinic acid (0.39 mg), trehalose dihydrate (29.8 mg) and tromethamine for pH adjustment to 5.0.
  • 0.327 mL containing 1.4 mg lonapegsomatropin-tcgd, succinic acid (0.39 mg) trehalose dihydrate (29.1 mg) and tromethamine for pH adjustment to 5.0.
  • 0.327 mL containing 1.8 mg lonapegsomatropin-tcgd, succinic acid (0.39 mg) trehalose dihydrate (28.8 mg) and tromethamine for pH adjustment to 5.0.
  • 0.327 mL containing 2.1 mg lonapegsomatropin-tcgd, succinic acid (0.39 mg) trehalose dihydrate (28.4 mg) and tromethamine for pH adjustment to 5.0.
  • 0.327 mL containing 2.5 mg lonapegsomatropin-tcgd, succinic acid (0.39 mg) trehalose dihydrate (28.1 mg) and tromethamine for pH adjustment to 5.0.
  • 0.273 mL containing 3 mg lonapegsomatropin-tcgd, succinic acid (0.32 mg), trehalose dihydrate (22.7 mg) and tromethamine for pH adjustment to 5.0.
  • 0.327 mL containing 3.6 mg lonapegsomatropin-tcgd, succinic acid (0.39 mg), trehalose dihydrate (27.1 mg) and tromethamine for pH adjustment to 5.0.
  • 0.391 mL containing 4.3 mg lonapegsomatropin-tcgd, succinic acid (0.46 mg) and trehalose dihydrate (32.5 mg) and tromethamine for pH adjustment to 5.0.
  • 0.473 mL containing 5.2 mg lonapegsomatropin-tcgd, succinic acid (0.56 mg) and trehalose dihydrate (39.3 mg) and tromethamine for pH adjustment to 5.0.
  • 0.286 mL containing 6.3 mg lonapegsomatropin-tcgd, succinic acid (0.34 mg) and trehalose dihydrate (21.2 mg) and tromethamine for pH adjustment to 5.0.
  • 0.345 mL containing 7.6 mg lonapegsomatropin-tcgd, succinic acid (0.41 mg) and trehalose dihydrate (25.5 mg) and tromethamine for pH adjustment to 5.0.
  • 0.414 mL containing 9.1 mg lonapegsomatropin-tcgd, succinic acid (0.49 mg) and trehalose dihydrate (30.6 mg) and tromethamine for pH adjustment to 5.0.
  • 0.5 mL containing 11 mg lonapegsomatropin-tcgd, succinic acid (0.59 mg) and trehalose dihydrate (37 mg) and tromethamine for pH adjustment to 5.0.
  • 0.605 mL containing 13.3 mg lonapegsomatropin-tcgd, succinic acid (0.71 mg) and trehalose dihydrate (44.8 mg) and tromethamine for pH adjustment to 5.0.

12.1 Mechanism Of Action

SKYTROFA is a pegylated human growth hormone (somatropin) for once-weekly subcutaneous injection [see Clinical Pharmacology (12.3)].

Somatropin binds to the growth hormone (GH) receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Somatropin has direct tissue and metabolic effects, and indirect effects mediated by insulin-like growth factor-1 (IGF-1), including stimulation of chondrocyte differentiation and proliferation, stimulation of hepatic glucose output, protein synthesis and lipolysis. Somatropin stimulates skeletal growth in pediatric patients with growth hormone deficiency (GHD) as a result of effects on the growth plates (epiphyses) of long bones.

12.2 Pharmacodynamics

Somatropin released from SKYTROFA produces a linear IGF-1 dose response. In pediatric patients with GHD, with a dose change of 0.02 mg/kg/week on average resulting in a mean change in weekly average IGF-1 standard deviation score (SDS) of 0.17. In adults with GHD, a dose change of 1 mg/week results in a mean change in weekly average IGF-1 SDS of 0.7 (range, 0.3 to 1.2).

At steady state, IGF-1 levels peak approximately 2 days post-dose, with the weekly average IGF-1 occurring approximately 4.5 days post-dose. IGF-1 levels are in the normal range for GHD patients for the majority of the week, similar to daily somatropin.

12.6 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of SKYTROFA or other growth hormone products.

Anti-lonapegsomatropin-tcgd antibodies were evaluated in samples collected every 3 months in phase 3 trials in pediatric patients with GHD receiving SKYTROFA. Mean duration of exposure to SKYTROFA was 70.2 weeks. Of the 304 patients with post-baseline assessments, 19 (6.3%) showed detectable binding antibodies to lonapegsomatropin-tcgd. No apparent correlation of anti-lonapegsomatropin-tcgd antibodies to adverse events or loss of efficacy was observed. No neutralizing antibodies to SKYTROFA were detected.

Of the 247 adult patients with GHD, treated with SKYTROFA and with post-baseline assessments, antibodies against lonapegsomatropin-tcgd were detected in 14 patients (5.7%, mean duration of exposure was 47.7 weeks). There was no identified clinically significant effect of anti-lonapegsomatropin-tcgd antibodies on the safety and efficacy of SKYTROFA. No neutralizing antibodies to SKYTROFA were detected.

13.1 Carcinogenicity, Mutagenesis, Impairment Of Fertility

Carcinogenicity studies have not been conducted with lonapegsomatropin-tcgd.

Lonapegsomatropin-tcgd was not mutagenic in the Ames test, in the human chromosomal aberration assay or in the rat bone marrow micronucleus test.

In an animal fertility study, lonapegsomatropin-tcgd was administered via subcutaneous injection to male and female rats before cohabitation, through mating to implantation.

Lonapegsomatropin-tcgd did not affect fertility or early embryo-fetal development at doses up to 20-fold the clinical pediatric dose of 0.24 mg/kg/week and approximately 46-fold the maximum clinical therapeutic dose for adult GHD of 6.3 mg hGH/week.

14.1 Treatment-Naïve Pediatric Patients With Growth Hormone Deficiency (Nct02781727)

A multi-center randomized, open-label, active-controlled, parallel-group phase 3 study was conducted in 161 treatment-naïve, prepubertal pediatric subjects with growth hormone deficiency (GHD); 105 subjects received once-weekly SKYTROFA, and 56 received daily somatropin. The dose in both arms was 0.24 mg/kg/week. The primary efficacy endpoint was annualized height velocity at Week 52.

The subjects ranged in age from 3.2 to 13.1 years with a mean of 8.5 years. One hundred thirty-two (82%) subjects were male and 29 (18%) were female. One subject was Asian, three were Black or African American, 152 were Caucasian, and five were categorized as "other." The subjects had a mean baseline height SDS (standard deviation score) of -2.9.

Treatment with once-weekly SKYTROFA for 52 weeks resulted in an annualized height velocity of 11.2 cm/year. Subjects treated with daily somatropin achieved an annualized height velocity of 10.3 cm/year after 52 weeks of treatment. Refer to Table 5.

Table 5: Annualized Height Velocity at Week 52 in Pediatric Treatment-Naïve Subjects with Growth Hormone Deficiency
Once-Weekly SKYTROFA (N = 105)Daily Somatropin (N = 56)Estimate of Treatment Difference (95% CI) (SKYTROFA minus Daily Somatropin)
Annualized Height Velocity (cm/year)

The estimates of least squares (LS) means and 95% confidence interval (CI) are from an ANCOVA model that included baseline age, peak GH levels (log transformed) at stimulation test, baseline height SDS – average SDS of parental height as covariates, and treatment and sex as factors. Missing data were imputed with multiple imputation method.

11.210.30.9
(0.2-1.5)

Height SDS (change from baseline) was 1.1 in the SKYTROFA arm and 0.96 in the daily somatropin arm at Week 52. Refer to Table 6.

Table 6: Height SDS over 52 Weeks in Pediatric Treatment-Naïve Subjects with Growth Hormone Deficiency
Once-Weekly SKYTROFA
(N = 105)
Daily Somatropin
(N = 56)
Abbreviations: SDS, standard deviation score.
Height SDS, baseline-2.9 -3.0
Height SDS, change from baseline

Height SDS, change from baseline: The estimates of LS means are from an ANCOVA model that included baseline age, peak GH levels (log transformed) at stimulation test and baseline height SDS as covariates, and treatment and sex as factors.

1.10.96

14.2 Adults With Growth Hormone Deficiency (Nct05171855)

A multi-center, randomized, parallel-group, placebo-controlled (double-blind), phase 3 study was conducted in 259 adults with GHD. Eighty-nine subjects received once-weekly SKYTROFA, 84 subjects received once-weekly placebo, and 86 subjects received open-label daily somatropin.

The mean (range) age at enrollment was 43 (23 to 81) years old, with 119 (46%) females (55 on oral estrogen) and 140 (54%) males, and the (SD) baseline body mass index of 28 (6.3) kg/m2. One subject was American Indian or Alaska Native, 1 was Black or African American, 28 were Asian, and 218 were Caucasian.

The primary efficacy endpoint, change in trunk percent (%) fat was measured by dual X-ray absorptiometry from baseline to Week 38 in the SKYTROFA group, compared to the placebo group (see Table 7).

Table 7: Change in Trunk Percent Fat from Baseline After 38 Weeks of Treatment in Adults with Growth Hormone Deficiency – SKYTROFA vs. Placebo
Change from Baseline at Week 38 Once-Weekly SKYTROFA
(N = 89)
Once-Weekly Placebo
(N = 84)
LS Mean Difference [95% CI]P-value
Abbreviations: LS, least squares; CI, confidence interval; kg, kilogram.
Trunk percent fat (%)

The estimates of least squares (LS) means and 95% confidence interval (CI) are from an ANCOVA model that included treatment arm, region (North America, Europe, Asia-Pacific), baseline age group, gender, concomitant oral estrogen at screening (yes vs. no), and adult GHD onset (adult vs. childhood) and corresponding baseline variable as a covariate. Missing data were imputed with multiple imputation method.

-1.70.4-2.0 [-2.9, -1.1]< 0.0001

Patients treated with daily somatropin achieved a change in trunk percent fat of -3.1% after 38 weeks. No formal statistical comparison between SKYTROFA and daily somatropin was conducted.

Change in total body lean mass and trunk fat mass from baseline after 38 weeks of treatment were secondary efficacy endpoints.

At 38 weeks, the change from baseline in total body lean mass was +1.6 kg for lonapegsomatropin and -0.1 kg for placebo (LS mean difference of 1.7 kg with 95% CI of 1.0 to 2.5, p-value < 0.0001).

At 38 weeks, the change from baseline in trunk fat mass was -0.5 kg for lonapegsomatropin and +0.2 kg for placebo (LS mean difference of -0.7 kg with 95% CI of -1.2 to -0.2, p-value = 0.005).

After 38 weeks, SKYTROFA treatment in adults with GHD resulted in normalization of IGF-1 SDS to 1.4 compared to -2.6 in placebo-treated patients. See Table 8.

Table 8: IGF-1 SDS at Baseline and after 38 Weeks of Treatment in Adults with Growth Hormone Deficiency – SKYTROFA vs. Placebo
Time PointOnce-Weekly SKYTROFA
(N = 89)
Once-Weekly Placebo
(N = 84)
Abbreviations: SD, standard deviation; SDS, standard deviation score.
Baseline IGF-1 SDS, mean (SD)-2.6 (1.0)-2.7 (1.2)
Week 38 IGF-1 SDS, mean (SD)

Sampling time corresponded to weekly average IGF-1 SDS for SKYTROFA.

1.4 (1.9)-2.6 (1.3)

The mean (SD) IGF-1 SDS level in daily somatropin treated patients was -2.82 (1) at baseline and 0.49 (1.98) at 38 weeks. No formal statistical comparison between SKYTROFA and daily somatropin was conducted.

Storage And Handling

Storage and Handling

  • For patients: Refrigerate SKYTROFA cartridges at 36°F to 46°F (2°C to 8°C) in the outer carton to protect from light until the expiration date. Do not freeze. Alternatively, SKYTROFA outer carton containing blistered cartridges may be stored at room temperature [up to 86°F (30°C)] for up to 6 months and can be returned to refrigeration within the 6 months. Write the date first removed from the refrigerator in the space provided on the outer carton. Do not use SKYTROFA beyond the expiration date or 6 months after the date it was first removed from refrigeration (whichever is earlier).
  • For pharmacy long-term storage: Store SKYTROFA cartridges refrigerated at 36°F to 46°F (2°C to 8°C) in the outer carton to protect from light until the expiration date. Do not freeze.

Instructions For Use

Keep Track of Your InjectionsInstructions
for Use
Image (Skytrofa 01)

Image (Skytrofa 01)

Image (Skytrofa 02)

Image (Skytrofa 02)

Image (Skytrofa 03)

Image (Skytrofa 03)

  • Important Information
  • Before You Begin
  • Setting Up
    • Step-by-Step Guide

      Image (Skytrofa 04)

      Image (Skytrofa 04)

      • Troubleshooting
      • Cleaning and Maintenance
      • Charging and Charging Cable
      • Storing
        • Product Safety
        • Expiration
        • EMC Compliance Levels
        • Technical Specification
        • Symbols
        • Warranty and Disclaimer
        • Parts Overview
        • Introduction

          Intended Purpose and Device Description:

          The SKYTROFA Auto-Injector is intended to automate the mixing (reconstitution) and injection under the skin (subcutaneous use) of lonapegsomatropin in patients prescribed one-time weekly growth hormone therapy.

          Injections are given under the skin (subcutaneously) one-time weekly in the abdomen, thighs, or buttocks.

          The intended users are patients prescribed with SKYTROFA, caregivers, and healthcare providers.

          Always use SKYTROFA exactly as your healthcare provider has told you. If you are unsure about your medicine, contact your healthcare provider.

          Consult your healthcare provider to be advised to perform self-administration or administration by your caregiver.

          The auto-injector is an electromechanical, reusable, single-patient use, and single-dose delivery device designed for personal home use. This means that a patient or caregiver can give injections at home without a healthcare provider present.

          A healthcare provider can use the auto-injector in a non-emergency clinical setting to inject a patient or demonstrate device use.

          Contraindications and Side Effects

          For more information on SKYTROFA contraindications, side effects, disease, self-care, summary of safety, and clinical performance, please refer to the information enclosed with your medicine or contact your healthcare provider.

          If you get any side effects, contact your healthcare provider.

          Step-by-step Instructions for the SKYTROFA Auto-Injector

          Read and follow this Instructions for Use that comes with your auto-injector before you start using it. This information does not replace talking to your healthcare provider about your medical condition or your treatment.

          The back cover of this Instructions for Use folds out for reference while you read the rest of the instructions.

          If you have any questions about the auto-injector, the medicine, or these instructions, please contact your healthcare provider or Ascendis Pharma Customer Support. For contact information

          Image (Skytrofa 05)

          Image (Skytrofa 05)

          back cover.

          Getting Started

          Page
          Important Information6
          Before You Begin9
          Setting Up12

          Important Information

          Image (Skytrofa 06)

          Image (Skytrofa 06)

          Important information about your SKYTROFA Auto-Injector:

          Do not use the SKYTROFA Auto-Injector for the first time until you receive training from a healthcare provider. Follow this Instructions for Use for the auto-injector to avoid getting an injury, infection, or incorrect dose.

          The auto-injector can only be used with SKYTROFA Cartridges and needles that are prescribed by your healthcare provider. Cartridges and needles come together in the same packaging. Follow the instructions that come with SKYTROFA Cartridges. If refrigerated, take the cartridge out of the refrigerator and leave at room temperature for 15 minutes before use.

          Do not use your auto-injector with other medicines or needles than provided in the SKYTROFA Cartridge pack.

           
          Image (Skytrofa 07)

          Image (Skytrofa 07)

          Your weekly dose may require that you use 2 cartridges.
          Image (Skytrofa 08)

          Image (Skytrofa 08)

          When this warning symbol is seen, safety instructions must be followed. Otherwise, serious safety hazardous situations and injuries may occur.
          Image (Skytrofa 09)

          Image (Skytrofa 09)

          Do not share your auto-injector with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
          Image (Skytrofa 10)

          Image (Skytrofa 10)

          Keep out of the reach of children.
          This product contains small parts that may present a choking hazard to small children. The cable can present a strangulation hazard.
          Image (Skytrofa 11)

          Image (Skytrofa 11)

          Do not use any charger or charging cables other than those included with your auto-injector. Read more on page 65.
          Image (Skytrofa 12)

          Image (Skytrofa 12)

          Do not use or place the auto-injector closer than 12 inches (30 cm) to microwave ovens or electronic equipment with antennas such as Wi-Fi transceivers. The auto-injector might not work the right way.
          Image (Skytrofa 13)

          Image (Skytrofa 13)

          When this precaution symbol is seen, safety instructions must be followed. Otherwise, safety hazardous situations and injuries and potential damage to the auto-injector or other property may occur.
          Image (Skytrofa 14)

          Image (Skytrofa 14)

          Do not reuse needles.
          Image (Skytrofa 15)

          Image (Skytrofa 15)

          Do not use a cartridge if it has been dropped or you think it may be damaged.
          Image (Skytrofa 16)

          Image (Skytrofa 16)

          Do not point the auto-injector at yourself or other people, except when you are ready to inject, to avoid needle stick injury.
          Image (Skytrofa 17)

          Image (Skytrofa 17)

          If your auto-injector turns off automatically, press and release the green button to turn it on again and read page 60 to proceed.
          Image (Skytrofa 18)

          Image (Skytrofa 18)

          If the auto-injector packaging has been damaged or unintentionally opened before first using it, please call Ascendis Pharma Customer Support. For contact information

          Image (Skytrofa 19)

          Image (Skytrofa 19)

          back cover.

          Before You Begin

          The SKYTROFA Auto-Injector

          Your healthcare provider will inform you that the SKYTROFA Auto-Injector, which comes in a separate package, is required for injecting the prescribed the SKYTROFA medicine.

          The SKYTROFA Auto-Injector is exclusively for use with SKYTROFA Cartridge (medicine).

          The SKYTROFA Auto-Injector automates part of the procedure for injecting SKYTROFA medicine.

          The SKYTROFA Cartridge

          The medicine SKYTROFA comes in a one-time use cartridge "SKYTROFA Cartridge". The cartridge has 2 chambers, 1 filled with powder and 1 filled with water. The auto-injector automatically mixes the powder and the water during mixing steps, making it ready for injection. Each SKYTROFA Cartridge pack contains 4 cartridges packed in individual blisters.

          The Needle

          The single-use needle comes with SKYTROFA Cartridges and is used for screwing on the cartridge to inject the medicine. Each SKYTROFA Cartridge pack contains 6 needles including 2 spare needles.

          Contact your healthcare provider if you need more SKYTROFA consumables.

          Image (Skytrofa 20)

          Image (Skytrofa 20)


                                                                                                               Figure A

          Product Overview

          Image (Skytrofa 21)

          Image (Skytrofa 21)


                                                                                         Figure B

          Setting Up

          • 1.Remove the SKYTROFA Auto-Injector from the package.
            • Use the auto-injector at room temperature between 59°F to 86°F (15°C to 30°C).
            • 2.Connect the USB (large end of the cable) to the charger (only use the provided charger). Plug the charger into a power outlet. Connect the Micro-USB (small end of the cable) to the back of the auto-injector. For protection, charge the auto-injector with the protective cover on (see Figure C).
              • For more information on charging

                Image (Skytrofa 22)

                Image (Skytrofa 22)

                page 65.
                Image (Skytrofa 23)

                Image (Skytrofa 23)


                                                                                                                      Figure C

              • 3.Fully charge the auto-injector before using it for the first time. This will take 2 hours and 30 minutes. When the battery icon located at the base of the auto-injector (see Figure D) is flashing orange or green, it is charging. When it shows constant green, the auto-injector is fully charged and is ready to use after the charging cable is unplugged.
                • When fully charged, the battery should last for at least 3 injections.
                • When traveling, bring regional adaptors for the auto-injector charger to connect to the local power outlet.
                • The auto-injector cannot be used when connected to the charger.

                  Image (Skytrofa 24)

                  Image (Skytrofa 24)

                  Figure D

                • 4.Find a quiet place where you can perform your injection.
                • 5.Gather your supplies and place them on a flat, hard, clean surface.
                  Supplies needed for an injection:
                  From SKYTROFA Auto-Injector packaging
                  (see Figure B):
                  • 1 SKYTROFA Auto-Injector
                  • From SKYTROFA Cartridge pack
                    (see Figure E):
                    • 1 SKYTROFA Cartridge
                    • 1 Omnican fine 0.25 mm × 4 mm (31G × 5/32") B. Braun needle
                    • Other supplies (not included)
                      (see Figure E):
                      • 1 Alcohol Wipe
                      • 1 Sharps Container
                      •  

                        Image (Skytrofa 25)

                        Image (Skytrofa 25)

                        If your weekly dose requires 2 cartridges, you will need the following additional supplies:

                        • 1 SKYTROFA Cartridge
                        • 1 Omnican fine 0.25 mm × 4 mm (31G × 5/32") B. Braun needle
                        • 1 Alcohol Wipe
                        • Supplies Needed for Each Injection

                          Image (Skytrofa 26)

                          Image (Skytrofa 26)


                                                                                                                                Figure E

                          Image (Skytrofa 27)

                          Image (Skytrofa 27)

                          Image (Skytrofa 28)

                          Image (Skytrofa 28)

                          Does Your Weekly Dose Require 2 Cartridges?

                          Your healthcare provider may prescribe a dose that requires use of the medicine in 2 cartridges.
                          If you have been prescribed a dose that requires 2 cartridges:
                          • Take your first injection (Step 1 to Step 11, pages 20–47).
                          • Then take your second injection by repeating Step 1 to Step 11 with a new cartridge and needle.
                          • After your second injection, continue to Step 12 (page 48).
                          Figure F

                          How to Use

                          Step-by-Step GuidePage
                          Prepare20
                          Mix30
                          Inject38
                          After Injection44
                          Image (Skytrofa 29)

                          Image (Skytrofa 29)

                          Prepare

                          1 Check and assemble cartridge and needle

                          Image (Skytrofa 30)

                          Image (Skytrofa 30)


                                                                                                                                Figure G

                          1.1Check the expiration date and cartridge dose on the cartridge packaging (see Figure G).
                          Image (Skytrofa 31)

                          Image (Skytrofa 31)

                          Do not use if the dose is not as prescribed.
                          Remove the SKYTROFA Cartridge from the packaging according to the instructions on its lid.
                          If refrigerated, take the cartridge out of the refrigerator and leave at room temperature for 15 minutes before use.
                          Do not use if the expiration date has passed on the cartridge.
                          • If you are unsure about your dose, contact your healthcare provider.
                          • If you are unsure about the medicine expiration date, please call Ascendis Pharma Customer Support. For contact information

                            Image (Skytrofa 32)

                            Image (Skytrofa 32)

                            back cover.

                          1.2Check the expiration date on the needle. Peel off the paper from the needle by hand (see Figure H).

                          Image (Skytrofa 33)

                          Image (Skytrofa 33)

                          Be careful with the exposed needle to avoid needle stick injury and infection.

                          Image (Skytrofa 34)

                          Image (Skytrofa 34)

                          Do not use the needle if:

                          • The protective paper is broken, not fully sealed, or not removed by hand.
                          • The expiration date has passed.

                          Image (Skytrofa 35)

                          Image (Skytrofa 35)

                          Do not use a bent needle.
                          Image (Skytrofa 36)

                          Image (Skytrofa 36)


                                                                                                                 Figure H

                          1.3Screw the needle straight on the cartridge by turning clockwise until there is a tight fit (see Figure I and J).
                          Image (Skytrofa 37)

                          Image (Skytrofa 37)

                          Do not remove the plastic needle cover. You will need it to insert the cartridge into the SKYTROFA Auto-Injector. Check the needle is screwed tight on the cartridge.
                          Image (Skytrofa 38)

                          Image (Skytrofa 38)

                          Do not use the needle if it has touched anything other than the injection site.

                          Image (Skytrofa 39)

                          Image (Skytrofa 39)


                                                                                                                               Figure I

                          Check the needle is screwed tight on the cartridge (see Figure J).

                          Image (Skytrofa 40)

                          Image (Skytrofa 40)


                                                                                                                               Figure J

                          2 Turn on the auto-injector

                          Image (Skytrofa 41)

                          Image (Skytrofa 41)


                                                                                                                     Figure K

                          2.1Disconnect the auto-injector from the charger when charged.
                          • The auto-injector cannot be used when connected to the charger.
                          2.2Find a quiet place where you can give your injection. Use the auto-injector at room temperature between 59°F to 86°F (15°C to 30°C).
                          2.3Remove the protective cover. Place the auto-injector upright on a flat surface.
                          2.4Press and release the green button to turn on the auto-injector (see Figure K).
                          • You will hear a humming sound. The battery icon

                            Image (Skytrofa 42)

                            Image (Skytrofa 42)

                            and the 3 icons above the green button will light up. Then all of the icons will turn off, except the battery icon.

                          • You will hear 2 loud beeps and the green top will start flashing. The auto-injector is ready for use.
                          • If the auto-injector is not active for 6 minutes, it will turn off. Press the green button to turn it on again.
                          2.5

                          Check the battery icon on the base of the auto-injector to see if it is charged. The battery icon

                          Image (Skytrofa 43)

                          Image (Skytrofa 43)

                          is green when the auto-injector is ready to use:

                          Image (Skytrofa 44)

                          Image (Skytrofa 44)

                          Constant Green
                          Battery is fully charged.
                          The auto-injector is ready to use.
                          Image (Skytrofa 45)

                          Image (Skytrofa 45)

                          Flashing Green
                          At least 1 injection remaining, but charging is recommended after use.
                          Image (Skytrofa 46)

                          Image (Skytrofa 46)

                          Flashing Orange
                          Battery needs charging.

                          If no icons light up

                          Image (Skytrofa 47)

                          Image (Skytrofa 47)

                          page 56.

                          If you see flashing icons (other than the battery)

                          Image (Skytrofa 48)

                          Image (Skytrofa 48)

                          pages 58–59.

                          3 Insert cartridge with attached needle

                          Image (Skytrofa 49)

                          Image (Skytrofa 49)

                          3.1Insert the cartridge.
                          Image (Skytrofa 50)

                          Image (Skytrofa 50)

                          Insert the cartridge into the flashing green top by pushing straight down with the needle cover still on (see Figure L).
                          3.2Click the cartridge into place.
                          Image (Skytrofa 51)

                          Image (Skytrofa 51)

                          Make sure the cartridge is pushed all the way down until you hear a click (see Figure M).
                          • You will hear a click, the green top will stop flashing, the green mixing icon

                            Image (Skytrofa 52)

                            Image (Skytrofa 52)

                            will light up, and the battery icon
                            Image (Skytrofa 53)

                            Image (Skytrofa 53)

                            will switch off.

                          Image (Skytrofa 54)

                          Image (Skytrofa 54)

                          Do not insert the cartridge without attaching the needle fully. If you did not attach the needle, push the cartridge to release it and continue with Step 1.2 (page 21).
                          Image (Skytrofa 55)

                          Image (Skytrofa 55)

                          Do not attempt to insert the charging cable in the auto-injector if a cartridge has been inserted.
                          3.3After the click, remove your finger from the cartridge (see Figure N).
                          • You will hear a repeating notification sound if the auto-injector is not standing upright. Keep the auto-injector standing upright on a flat surface.
                          Image (Skytrofa 56)

                          Image (Skytrofa 56)

                          If your auto-injector turns off automatically, press and release the green button to turn it on again, then read Situation A

                          Image (Skytrofa 57)

                          Image (Skytrofa 57)

                          page 61.

                          Image (Skytrofa 58)

                          Image (Skytrofa 58)

                          If you see a flashing orange mixing icon

                          Image (Skytrofa 59)

                          Image (Skytrofa 59)

                          page 58.
                          If you cannot insert the cartridge, check if an orange plug is still attached to the cartridge. If an orange plug is still attached to the cartridge, remove it by pulling it straight off (see Figure O). The orange plug only protects the cartridge during transportation.

                          Image (Skytrofa 60)

                          Image (Skytrofa 60)


                                                                                                                                                         Figure O

                          Do not use the auto-injector if you cannot insert the cartridge. Please call Ascendis Pharma Customer Support. For contact information

                          Image (Skytrofa 61)

                          Image (Skytrofa 61)

                          back cover.

                          Mix

                          4 Wait while mixing

                          Image (Skytrofa 62)

                          Image (Skytrofa 62)


                                                                                                                             Figure P

                          4.1Wait 4 to 8 minutes for the auto-injector to mix your medicine. The progress bar will gradually light up, and you will hear steady ticking during mixing (see Figure P).
                          • Make sure the auto-injector is standing upright on a flat surface. If the auto-injector is not upright, the medicine mixing will pause.
                          Image (Skytrofa 63)

                          Image (Skytrofa 63)

                          If you see a slowly flashing green mixing icon and the progress bar is frozen

                          Image (Skytrofa 64)

                          Image (Skytrofa 64)

                          page 54.

                          Image (Skytrofa 65)

                          Image (Skytrofa 65)

                          If you see a flashing orange mixing icon

                          Image (Skytrofa 66)

                          Image (Skytrofa 66)

                          page 58.

                          4.2The auto-injector has finished the automatic part of the mixing when you hear 2 loud beeps and the entire progress bar flashes.
                          4.3Continue with Step 5 (page 32) immediately after automatic mixing is completed.
                          If you wait for more than 2 hours before completing the steps for mixing the medicine by hand (Step 5), the auto-injector will automatically cancel the procedure.
                          If this happens, the cartridge will be released and cannot be used. To remove the cartridge, see Step 10 (page 44).
                          If you still need to inject after the auto-injector has canceled the procedure, go back to Step 1 and use a new cartridge (page 20).
                          Image (Skytrofa 67)

                          Image (Skytrofa 67)

                          If your auto-injector turns off automatically, press and release the green button to turn it on again, then read Situation B

                          Image (Skytrofa 68)

                          Image (Skytrofa 68)

                          page 61.

                          5 Turn the auto-injector up and down
                          Turn the auto-injector up and down, listening for a tick sound each up and down cycle to make sure the turns are correct.
                          Image (Skytrofa 69)

                          Image (Skytrofa 69)

                          Turn up and down correctly 5 to 10 times until you hear 2 loud beeps and the whole progress bar, except the top element, lights up.
                          Do not press the green button.
                          Figure Q
                          5.1Turn the auto-injector up and down to mix the medicine by hand. You will hear a 'tick' sound each time you turn the auto-injector up and down correctly. To mix the medicine correctly:
                          • Each turn up and down should take no more than 2 seconds, followed by a tick sound.
                          • The auto-injector should point straight down and straight up (see Figure Q).

                          • The progress bar, except the top element, will light up as you turn the auto-injector up and down correctly.
                            Do not press the green button. Pressing and holding the green button for 8 seconds will cancel mixing, and you cannot reuse the cartridge.
                            After 5 to 10 correct turns, you will hear 2 loud beeps and the progress bar, except the top element, will light up.
                          Image (Skytrofa 70)

                          Image (Skytrofa 70)

                          If your auto-injector turns off automatically, press and release the green button to turn it on again. Read Situation B or C to find the corresponding lit-up icons

                          Image (Skytrofa 71)

                          Image (Skytrofa 71)

                          page 61 and 62.

                          Image (Skytrofa 72)

                          Image (Skytrofa 72)

                          If you see a flashing orange mixing icon

                          Image (Skytrofa 73)

                          Image (Skytrofa 73)

                          page 58.

                          5.2Continue with Step 6 (page 36) immediately after you finish mixing by hand.
                          If you wait more than 2 hours before performing Step 6 to Step 9 (pages 36–43), the auto-injector will automatically cancel the procedure. If this happens, the cartridge will be released and cannot be used. To remove the cartridge, see Step 10 (page 44).
                          • If you still need to inject after the auto-injector has canceled the procedure, go back to Step 1 and use a new cartridge (page 20).
                          6 Finish mixing

                          Image (Skytrofa 74)

                          Image (Skytrofa 74)

                          6.1Keep the auto-injector upright for automatic air removal (see Figure R). Wait until you hear 2 loud beeps and the entire progress bar lights up.
                          Image (Skytrofa 75)

                          Image (Skytrofa 75)

                          If you see a slowly flashing green mixing icon and the progress bar is frozen

                          Image (Skytrofa 76)

                          Image (Skytrofa 76)

                          page 54.

                          Image (Skytrofa 77)

                          Image (Skytrofa 77)

                          If you see a flashing orange mixing icon

                          Image (Skytrofa 78)

                          Image (Skytrofa 78)

                          page 58.

                          6.2

                          Pull off the needle cover (see Figure S). The green eye icon

                          Image (Skytrofa 79)

                          Image (Skytrofa 79)

                          will light up. Removing the needle cover will allow you to check the mixed medicine in the inspection window (Step 7 on page 38).
                          Do not twist the needle cover off. If you have trouble removing the needle cover, gently pull up the green top.

                          Image (Skytrofa 80)

                          Image (Skytrofa 80)

                          Keep the needle cover for later use. It is needed to safely remove the cartridge after injection.
                          Image (Skytrofa 81)

                          Image (Skytrofa 81)

                          If your auto-injector turns off automatically, press and release the green button to turn it on again. Read Situation D or E to find the corresponding lit-up icons

                          Image (Skytrofa 82)

                          Image (Skytrofa 82)

                          page 62 and 63.

                          Inject
                          7 Check mixed medicine

                          Image (Skytrofa 83)

                          Image (Skytrofa 83)


                                                                                                                         Figure T

                          7.1Check the mixed medicine in the inspection window on the side of the auto-injector (see Figure T).
                          The medicine should look colorless and clear. It may contain air bubbles. This is normal.
                          Image (Skytrofa 84)

                          Image (Skytrofa 84)

                          Be careful with the exposed needle to avoid needle stick injury and infection.
                          Do not inject the medicine if there are visible particles (medicine is not dissolved) or the mixed medicine is discolored.
                          If you see visible particles or the medicine is discolored:
                          • Cancel the injection procedure by pressing and holding the green button for 8 seconds. This will unlock the cartridge. Go to Step 10 (page 44).
                          • Get a new cartridge. Follow the instructions beginning at Step 1 (page 20).
                          Image (Skytrofa 85)

                          Image (Skytrofa 85)

                          If you see a flashing orange mixing icon

                          Image (Skytrofa 86)

                          Image (Skytrofa 86)

                          page 58.

                          8 Prepare for injection

                          Image (Skytrofa 87)

                          Image (Skytrofa 87)


                                                                                                                           Figure U

                          8.1Choose an injection site.
                          Image (Skytrofa 88)

                          Image (Skytrofa 88)

                          There are only 3 areas of your body you can inject into (see Figure U):
                          • Stomach (abdomen)
                          • Thighs
                          • Buttocks
                          • Change the injection site for every injection.
                          8.2Make sure your hands are clean using soap and water or hand sanitizer (see Figure V).

                          Image (Skytrofa 89)

                          Image (Skytrofa 89)


                                                                                                                         Figure V

                          8.3Clean the injection site with an alcohol wipe (see Figure W).
                          Image (Skytrofa 90)

                          Image (Skytrofa 90)

                          Do not inject in an injection site that has not been cleaned.
                          Image (Skytrofa 91)

                          Image (Skytrofa 91)

                          Do not touch the cleaned area before injecting.
                          Image (Skytrofa 92)

                          Image (Skytrofa 92)

                          Do not fan or blow on the cleaned area.
                          Image (Skytrofa 93)

                          Image (Skytrofa 93)

                          Inject directly into skin. Do not inject through clothes.

                          Image (Skytrofa 94)

                          Image (Skytrofa 94)


                                                                                                                         Figure W

                          9 Inject medicine

                          Image (Skytrofa 95)

                          Image (Skytrofa 95)

                          9.1

                          Press and hold the green top against the skin of the injection site to inject (see Figure X). Hold for 10 to 20 seconds until you hear 2 loud beeps and the green top flashes 2 times. The green check mark icon

                          Image (Skytrofa 96)

                          Image (Skytrofa 96)

                          will light up.

                          • The medicine is injected automatically when you press the green top against the skin.
                          • You will hear steady ticking and the progress bar will light up as you inject.
                          Image (Skytrofa 97)

                          Image (Skytrofa 97)

                          Do not remove the auto-injector from the injection site until the injection is finished to ensure you get your full cartridge dose.
                          The injection is finished when you hear 2 loud beeps and the green top flashes 2 times. The green check mark

                          Image (Skytrofa 98)

                          Image (Skytrofa 98)

                          will light up.

                          9.2Remove the auto-injector from the skin after the injection is finished (see Figure Y).
                          • After the injection is finished, the auto-injector makes a buzzing sound as it unlocks the cartridge. Wait until you hear 2 loud beeps, and the green top starts to flash.
                          Image (Skytrofa 99)

                          Image (Skytrofa 99)

                          If you see a slowly flashing green check mark icon and the progress bar is frozen

                          Image (Skytrofa 100)

                          Image (Skytrofa 100)

                          page 55.

                          Image (Skytrofa 101)

                          Image (Skytrofa 101)

                          If you see a flashing orange check mark icon

                          Image (Skytrofa 102)

                          Image (Skytrofa 102)

                          page 58.

                          After Injection
                          10 Remove cartridge

                          Image (Skytrofa 103)

                          Image (Skytrofa 103)

                          Image (Skytrofa 104)

                          Image (Skytrofa 104)

                          Be careful when handling needles to reduce the risk of needlestick injury and infection.
                          10.1Press down the needle cover into the flashing green top until you hear a click to remove the cartridge (see Figure Z).
                          • You will hear a click and see the green top stop flashing (see Figure Z).
                          • Do not twist the cartridge.
                          10.2Remove the used cartridge by pulling straight up (see Figure AA).
                          Image (Skytrofa 105)

                          Image (Skytrofa 105)

                          Do not remove the cartridge without using the needle cover.
                          • After you remove the cartridge, the battery icon

                            Image (Skytrofa 106)

                            Image (Skytrofa 106)

                            will display the battery level. The auto-injector turns off automatically.

                          Image (Skytrofa 107)

                          Image (Skytrofa 107)

                          Do not use the auto-injector if you cannot remove the cartridge as instructed. Please call Ascendis Pharma Customer Support. For contact information

                          Image (Skytrofa 108)

                          Image (Skytrofa 108)

                          back cover.

                          11 Check cartridge and throw away

                          Image (Skytrofa 109)

                          Image (Skytrofa 109)


                                                                                                                         Figure AB

                          11.1Check that the cartridge is empty of medicine (see Figure AB).
                          Image (Skytrofa 110)

                          Image (Skytrofa 110)

                          Do not use the auto-injector if there is medicine left in the cartridge after injection. Please call Ascendis Pharma Customer Support. For contact information

                          Image (Skytrofa 111)

                          Image (Skytrofa 111)

                          back cover.

                          11.2Put your used cartridge and needle in an FDA-cleared sharps disposal container right away after use (see Figure AB).
                          Image (Skytrofa 112)

                          Image (Skytrofa 112)

                          Do not throw away (dispose of) opened or used needles and cartridges in your household trash.
                          Do not recycle your used sharps disposal container.
                          If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
                          • Made of a heavy-duty plastic
                          • Can be closed with a tight-fitting, puncture-resistant lid without sharps being able to come out
                          • Upright and stable during use
                          • Leak-resistant
                          • Properly labeled to warn of hazardous waste inside the container
                          • When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how to throw away used needles and syringes. For more information about safe sharps disposal, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
                          Image (Skytrofa 113)

                          Image (Skytrofa 113)

                          Healthcare providers, relatives, and other caregivers should follow this Instructions for Use for removal and throwing away (disposal) of needles to prevent needlestick injury and infection.
                          Image (Skytrofa 114)

                          Image (Skytrofa 114)

                          Does Your Weekly Dose Require 2 Cartridges?
                          Then take the second injection by repeating Step 1 to Step 11 (pages 20–47) with a new cartridge and needle before continuing to Step 12.

                          12 Store the auto-injector

                          Image (Skytrofa 115)

                          Image (Skytrofa 115)


                                                                                                                         Figure AC
                          12.1

                          Make sure that the auto-injector is clean. If it is dirty or if medicine has been spilled onto it, clean with a damp cloth and wait until dry.
                          Do not place the auto-injector under water. For more information on cleaning

                          Image (Skytrofa 116)

                          Image (Skytrofa 116)

                          page 64.

                          12.2Put the protective cover on the auto-injector by sliding it straight down (see Figure AC).
                          12.3

                          Charge the auto-injector if the battery icon has been flashing before or after the injection. For more information about how to charge the auto-injector

                          Image (Skytrofa 117)

                          Image (Skytrofa 117)

                          page 65.

                          12.4

                          It is recommended to store the auto-injector at room temperature between 59°F to 86°F (15°C to 30°C), in between uses. Store with the protective cover on until the next injection. For more information about how to store the auto-injector

                          Image (Skytrofa 118)

                          Image (Skytrofa 118)

                          page 66.

                          12.5

                          Write down the date of every weekly dose taken under Keep Track of Your Injections

                          Image (Skytrofa 119)

                          Image (Skytrofa 119)

                          back cover fold out.

                          • When the auto-injector reaches its expiration date, maximum number of injections, or needs replacing, return it to the Ascendis Pharma Customer Support. For more information, see Expiration

                            Image (Skytrofa 120)

                            Image (Skytrofa 120)

                            page 72.

                          Troubleshooting and Care

                          Page
                          Troubleshooting52
                          Cleaning and Maintenance64
                          Charging and Charging Cable65
                          Storing66

                          Troubleshooting

                          - What do you see?

                          Image (Skytrofa 121)

                          Image (Skytrofa 121)

                          Image (Skytrofa 122)

                          Image (Skytrofa 122)


                          Image (Skytrofa 123)

                          Image (Skytrofa 123)


                          Image (Skytrofa 124)

                          Image (Skytrofa 124)

                          Orange flashing icons
                          If you see any of these

                          Image (Skytrofa 125)

                          Image (Skytrofa 125)

                          pages 58–59.

                          Image (Skytrofa 126)

                          Image (Skytrofa 126)

                          Orange battery icon
                          If you see this

                          Image (Skytrofa 127)

                          Image (Skytrofa 127)

                          page 57.

                          If the auto-injector turns off automatically, press and release the green button:
                          If the auto-injector is not responding with no icons lighting up

                          Image (Skytrofa 128)

                          Image (Skytrofa 128)

                          page 56.
                          If any progress bar elements or icons light up
                          Image (Skytrofa 129)

                          Image (Skytrofa 129)

                          page 61–63.

                          Image (Skytrofa 130)

                          Image (Skytrofa 130)


                          Image (Skytrofa 131)

                          Image (Skytrofa 131)

                          You see slowly flashing green mixing icon and the progress bar is frozen.
                          Image (Skytrofa 132)

                          Image (Skytrofa 132)

                          You hear a repeating notification sound.
                          Mixing paused (Step 4 on page 30 or Step 6 on page 36). If the SKYTROFA Auto-Injector is not in an upright position, mixing or air removal will pause (see Figure AD).
                          Do this: Place the auto-injector in an upright position and the mixing or air removal will continue.

                          Image (Skytrofa 133)

                          Image (Skytrofa 133)


                                                                                                                         Figure AD

                          Image (Skytrofa 134)

                          Image (Skytrofa 134)


                          Image (Skytrofa 135)

                          Image (Skytrofa 135)

                          You see a slowly flashing green check mark icon and the progress bar is frozen.
                          Image (Skytrofa 136)

                          Image (Skytrofa 136)

                          You hear a repeating notification sound.
                          Injection paused (Step 9 on page 42). If the green top is removed from the skin before completing the injection, the auto-injector will pause the injection (see Figure AE).
                          Do this: Press the green top against skin and the injection will start again. If the injection is not completed within 15 minutes, the auto-injector automatically cancels the injection.

                          Image (Skytrofa 137)

                          Image (Skytrofa 137)


                                                                                                                         Figure AE

                          Image (Skytrofa 138)

                          Image (Skytrofa 138)

                          You see a flashing green battery icon.
                          Charging recommended. There is enough battery for at least 1 injection.
                          Do this: Charge the auto-injector after the next injection.
                          Image (Skytrofa 139)

                          Image (Skytrofa 139)

                          You see a constant green battery icon.
                          Battery is fully charged. The auto-injector is ready to use (the battery icon turns off while the auto-injector is in use).
                          Do this: If you are charging the auto-injector, disconnect it from the charger.
                          You see no icons lighting up at all.
                          Either the auto-injector has turned off (the auto-injector will turn off if it is not active for 6 minutes without a cartridge loaded or for 3 minutes with a cartridge loaded) or the battery needs charging.

                          Do this: Press the green button to turn it on again.

                          • If you see a flashing orange battery icon, the battery needs charging. Read more

                            Image (Skytrofa 140)

                            Image (Skytrofa 140)

                            page 57.

                          • If you see any other icons or the progress bar light up, the auto-injector has timed out and turned off automatically. Read more

                            Image (Skytrofa 141)

                            Image (Skytrofa 141)

                            page 60.

                          Image (Skytrofa 142)

                          Image (Skytrofa 142)

                          You see a flashing orange battery icon. You hear a notification sound.
                          The battery needs charging.
                          Do this: Charge the auto-injector.
                          Insert the charging cable into the auto-injector at rear lower side and connect to a power outlet (see Figure AF). When the auto-injector has charged for 15 minutes and the battery icon flashes green, the auto-injector is ready to use for at least 1 injection after the charging cable is unplugged. When the battery icon shows constant green, the auto-injector is fully charged and lasts for at least 3 injections.

                          Image (Skytrofa 143)

                          Image (Skytrofa 143)


                                                                                                                         Figure AF

                          Image (Skytrofa 144)

                          Image (Skytrofa 144)


                          Image (Skytrofa 145)

                          Image (Skytrofa 145)

                          You see a flashing orange mixing icon.
                          Image (Skytrofa 146)

                          Image (Skytrofa 146)

                          You hear an error sound.
                          Either you have inserted a used cartridge, or you have canceled the mixing, or the auto-injector has canceled the injection, or the cartridge is damaged. The auto-injector cancels the injection 2 hours after automatic mixing (Step 4, page 30) or 2 hours after manual mixing (Step 5, page 32) is completed.

                          Do this: Remove the cartridge and wait for the device to turn off. Start again with a new, unused cartridge and make sure to screw on the needle straight and tightly.
                          Read more

                          Image (Skytrofa 147)

                          Image (Skytrofa 147)

                          page 20.

                          Image (Skytrofa 148)

                          Image (Skytrofa 148)


                          Image (Skytrofa 149)

                          Image (Skytrofa 149)

                          You see a flashing orange check mark icon.
                          Image (Skytrofa 150)

                          Image (Skytrofa 150)

                          You hear an error sound.
                          Either an injection error has happened (the needle is not screwed on tightly, or it is bent or blocked), or you have canceled the injection, or the auto-injector has canceled an injection that was not completed within 15 minutes.

                          Do this: Remove the cartridge and wait for the auto-injector to turn off. Start again with a new, unused cartridge and make sure to screw on the needle straight and tightly.
                          Read more

                          Image (Skytrofa 151)

                          Image (Skytrofa 151)

                          page 20.

                          Image (Skytrofa 152)

                          Image (Skytrofa 152)

                          Image (Skytrofa 153)

                          Image (Skytrofa 153)

                          You see 3 flashing icons alternating between green and orange.

                          Image (Skytrofa 154)

                          Image (Skytrofa 154)

                          Image (Skytrofa 155)

                          Image (Skytrofa 155)

                          Image (Skytrofa 156)

                          Image (Skytrofa 156)

                          Image (Skytrofa 157)

                          Image (Skytrofa 157)

                          You hear a repeating error sound.
                          If you see an orange flashing icon when you press the green button, the battery needs charging.The auto-injector might have timed out and turned off automatically. If so, it will light up in one of the five different ways you see on the next pages.
                          The auto-injector is near its expiration. The first time you see this, either there are 5 injections left or the auto-injector expires in 1 month.

                          Do this: Press and release the green button to proceed. The green top will start flashing. The auto-injector can be used as usual for the remaining injections. When there are no more injections left or the expiration date has passed, the auto-injector cannot be used. Please contact a healthcare provider or Ascendis Pharma Customer Support to receive a new auto-injector. For Ascendis Pharma contact information

                          Image (Skytrofa 158)

                          Image (Skytrofa 158)

                          back cover.

                          Image (Skytrofa 159)

                          Image (Skytrofa 159)


                          Image (Skytrofa 160)

                          Image (Skytrofa 160)

                          You see 3 flashing orange icons.
                          Image (Skytrofa 161)

                          Image (Skytrofa 161)

                          You hear an error sound.
                          Either the auto-injector has expired (the maximum number of injections has been reached or the lifetime of 5 years has passed) or a critical error has occurred.

                          Do this: Try to turn the auto-injector on (press and release the green button). If you still see 3 flashing orange icons, the auto-injector needs to be replaced. For disposal information

                          Image (Skytrofa 162)

                          Image (Skytrofa 162)

                          page 73. Please contact a healthcare provider or Ascendis Pharma Customer Support to receive a new auto-injector. For Ascendis Pharma contact information
                          Image (Skytrofa 163)

                          Image (Skytrofa 163)

                          back cover.

                          Image (Skytrofa 164)

                          Image (Skytrofa 164)

                          If you see no icons lighting up at all.
                          Either the auto-injector needs charging or it has timed out and turned off automatically.
                          Image (Skytrofa 165)

                          Image (Skytrofa 165)

                          Do this: Press and release the green button to turn the auto-injector on again.
                          Image (Skytrofa 166)

                          Image (Skytrofa 166)

                          1.

                          Do this: Read more

                          Image (Skytrofa 167)

                          Image (Skytrofa 167)

                          page 57.

                          Image (Skytrofa 168)

                          Image (Skytrofa 168)

                          2.
                          Do this: Read the next pages and find the way your device lights up and blinks.
                          Image (Skytrofa 169)

                          Image (Skytrofa 169)

                          Situation A
                          You see a flashing green mixing icon and a progress bar with the bottom first element lit up. You hear a repeating notification sound.
                          The auto-injector has not completed the automatic medicine mixing.
                          Do this: Keep the auto-injector standing upright on a flat surface. Go to

                          Image (Skytrofa 170)

                          Image (Skytrofa 170)

                          Step 4.1 on page 30.

                          Image (Skytrofa 171)

                          Image (Skytrofa 171)

                          Situation B
                          You see a constant green mixing icon and a flashing progress bar.
                          The auto-injector has not completed the manual mixing of the medicine.
                          Do this: Continue to turn the auto-injector up and down to mix the medicine by hand. Go to

                          Image (Skytrofa 172)

                          Image (Skytrofa 172)

                          Step 5.1 on page 32.

                          Image (Skytrofa 173)

                          Image (Skytrofa 173)

                          Situation C
                          You see a flashing green mixing icon and a constant progress bar lit up. You hear a repeating notification sound.
                          The auto-injector has not automatically removed the air.
                          Do this: Keep the auto-injector standing upright on a flat surface. Go to

                          Image (Skytrofa 174)

                          Image (Skytrofa 174)

                          Step 6.1 on page 36.

                          Image (Skytrofa 175)

                          Image (Skytrofa 175)

                          Situation D
                          You see a constant green mixing icon and a constant progress bar lit up.
                          You have not pulled off the needle cover within 3 minutes of completing automatic air removal.
                          Do this: Continue to pull off the needle cover. Go to

                          Image (Skytrofa 176)

                          Image (Skytrofa 176)

                          Step 6.2 on page 37.

                          Image (Skytrofa 177)

                          Image (Skytrofa 177)

                          Situation E
                          You see a constant green eye icon.
                          You have not started to inject within 3 minutes of pulling off the needle cover.
                          Do this: Continue to prepare and do the injection. Go to

                          Image (Skytrofa 178)

                          Image (Skytrofa 178)

                          Step 7 to Step 9, pages 38–43.

                          Cleaning and Maintenance
                          Cleaning the SKYTROFA Auto-Injector
                          If the auto-injector is dirty or if medicine has been spilled onto it, clean with a damp cloth. Before cleaning, the cartridge must be removed.
                          The green top needs to be cleaned on the outside and on the reachable part of the inside.
                          If medicine is spilled inside the auto-injector, turn it upside down to let the medicine run out.
                          Image (Skytrofa 179)

                          Image (Skytrofa 179)

                          Do not clean the auto-injector while charging. Keep the auto-injector dry.
                          Do not place the auto-injector in liquid.
                          Do not sterilize the auto-injector.
                          Maintenance of the SKYTROFA Auto-Injector
                          Image (Skytrofa 180)

                          Image (Skytrofa 180)

                          Do not open, try to repair, or change the auto-injector. The battery is not replaceable. Please call Ascendis Pharma Customer Support. For contact information

                          Image (Skytrofa 181)

                          Image (Skytrofa 181)

                          back cover.

                          Charging and Charging Cable
                          Charging the SKYTROFA Auto-Injector

                          Connect the USB (large end of the cable) to the charger. Plug the charger into a power outlet. Connect the Micro-USB (small end of the cable) to the rear of the auto-injector. For protection, charge the auto-injector with the protective cover on. Read more

                          Image (Skytrofa 182)

                          Image (Skytrofa 182)

                          pages 12–13.
                          Only charge the auto-injector when the battery icon is flashing green or orange. Read more
                          Image (Skytrofa 183)

                          Image (Skytrofa 183)

                          pages 56–57.

                          Image (Skytrofa 184)

                          Image (Skytrofa 184)

                          Do not use any charger or charging cables other than those included with your auto-injector. Other chargers or cables may create problems and may interfere with device operation.
                          Image (Skytrofa 185)

                          Image (Skytrofa 185)

                          Do not clean the auto-injector while charging. Keep the auto-injector dry.
                          Image (Skytrofa 186)

                          Image (Skytrofa 186)

                          Do not insert a cartridge when the auto-injector is connected to the charger.
                          Image (Skytrofa 187)

                          Image (Skytrofa 187)

                          Do not attempt to insert the charging cable in the auto-injector if a cartridge has been inserted.
                          Storing
                          Storing the SKYTROFA Auto-Injector
                          Image (Skytrofa 188)

                          Image (Skytrofa 188)

                          Keep out of the reach of children.
                          This product contains small parts that may present a choking hazard to small children. The cable can present a strangulation hazard.
                          Image (Skytrofa 189)

                          Image (Skytrofa 189)

                          Do not store the auto-injector closer than 12 inches (30 cm) to microwave ovens or electronic equipment with antennas such as Wi-Fi transceivers. The auto-injector may not work the right way.
                          Remove the cartridge from the auto-injector before storing.
                          Store with the protective cover on.
                          It is recommended to store the auto-injector at room temperature between 59°F to 86°F (15°C to 30°C), in between uses. If the auto-injector is stored at higher or lower temperatures, you should keep it at room temperature for 30 minutes before use with a cartridge. The auto-injector can be stored between 14°F to 104°F (-10°C to 40°C) if not in use.
                          Keep the protective cover on when traveling with the auto-injector.
                          Keep the auto-injector away from dirt, dust, and humid or wet places.
                          Keep the auto-injector, the charger, and the charging cable away from pets and pests.
                          Avoid refrigerating or freezing the auto-injector in between uses.
                          Image (Skytrofa 190)

                          Image (Skytrofa 190)

                          Avoid exposing the auto-injector to direct sunlight and extreme temperatures.
                          For technical details of the conditions under which the auto-injector can be used, stored, and transported

                          Image (Skytrofa 191)

                          Image (Skytrofa 191)

                          pages 77-79.
                          Storing the SKYTROFA Cartridge
                          For information on the SKYTROFA Cartridge storing, see instructions on the cartridge pack and blister.

                          Product Information

                          Page
                          Product Safety70
                          Expiration72
                          EMC Compliance Levels74
                          Technical Specification77
                          Symbols80
                          Warranty and Disclaimer84
                          Parts Overview85

                          Product Safety

                          Do not use the SKYTROFA Auto-Injector if the SKYTROFA Cartridge cannot be inserted or removed, or if the cartridge was not completely emptied during the last attempted injection.

                          Image (Skytrofa 192)

                          Image (Skytrofa 192)

                          Do not use the auto-injector if you think it may be damaged.
                          Image (Skytrofa 193)

                          Image (Skytrofa 193)

                          Do not open, try to repair, or change the auto-injector. The battery is not replaceable. Please call Ascendis Pharma Customer Support. For contact information

                          Image (Skytrofa 194)

                          Image (Skytrofa 194)

                          back cover.

                          Image (Skytrofa 195)

                          Image (Skytrofa 195)

                          Do not clean the auto-injector while charging. Keep the auto-injector dry.
                          Image (Skytrofa 196)

                          Image (Skytrofa 196)

                          Do not use or place the auto-injector closer than 12 inches (30 cm) to microwave ovens or electronic equipment with antennas such as Wi-Fi transceivers. The auto-injector might not work the right way.
                          Image (Skytrofa 197)

                          Image (Skytrofa 197)

                          Do not use a cartridge if it has been dropped or you think it may be damaged.
                          Image (Skytrofa 198)

                          Image (Skytrofa 198)

                          Do not expose the auto-injector to extreme temperatures. Keep the auto-injector away from heat and open flames. Keep it out of direct sunlight.
                          Do not place the auto-injector in liquid.
                          Do not wash the auto-injector in a dishwasher.
                          Expiration

                          The SKYTROFA Auto-Injector has an expiration date (5 years after the manufacturing date) or a maximum of 210 injections, whichever comes first. The expiration date is located at the bottom of the auto-injector and is indicated by year (YYYY), month (MM), and date (DD), printed as YYYY-MM-DD.
                          When there are 5 injections or less than 1 month left, the auto-injector will indicate this when turned on. Read more

                          Image (Skytrofa 199)

                          Image (Skytrofa 199)

                          page 59.
                          The auto-injector may be used for the remaining 5 injections. After the final injection or after the expiration date, your auto-injector has to be replaced. Please contact a healthcare provider or Ascendis Pharma Customer Support to receive a new auto-injector. For contact information
                          Image (Skytrofa 200)

                          Image (Skytrofa 200)

                          back cover.
                          Image (Skytrofa 201)

                          Image (Skytrofa 201)


                          The auto-injector contains electrical and electronic components, including a non-replaceable battery.
                          Do not throw away (dispose) in household trash.
                          When the auto-injector reaches its expiration date, maximum number of injections, or needs replacing, return it to the Ascendis Pharma Customer Support. Contact Ascendis Pharma Customer Support for instructions on how to return properly. For contact information
                          Image (Skytrofa 202)

                          Image (Skytrofa 202)

                          back cover.

                          EMC Compliance Levels

                          The auto-injector is intended for use in the electromagnetic environment specified below. The user of the auto-injector should ensure that it is used in such an environment.

                          Electromagnetic Compatibility (EMC) Compliance LevelsBasic EMC Standard
                          EMC - RF Field radiated emission in 10 m (maximum):
                          a) 30 MHz to 230 MHz: ≤ 30 dB (μV/m) quasi-peak.
                          b) 230 MHz to 1 GHz: ≤ 37 dB (μV/m) quasi-peak.
                          c) Internal source <108 MHz
                          Compliance levels according to CISPR11, Group1, Class B.
                          IEC 60601-1-2 Edition 4.1/ EN 60601-1-2:2015/ A1:2021 CISPR 11 / EN 55011 EN ISO 11608- 4:2022
                          EMC - RF Field radiated immunity - Electrical field:
                          a) 10 V/m 80-2700 MHz.
                              1 kHz 80% AM
                          IEC 60601-1-2 Edition 4.1/ EN 60601-1-2:2015/ A1:2021 IEC 61000-4-3 EN ISO 11608- 4:2022
                          EMC - Power Frequency Magnetic field, Immunity:
                          a) 30 A/m
                          IEC 60601-1-2 Edition 4.1/ EN 60601-1-2:2015/ A1:2021 IEC 61000-4-3 EN ISO 11608- 4:2022
                          EMC - Fast transients and bursts:
                          a) Fast transients and bursts ±2 kV ac mains
                          IEC 60601-1-2 Edition 4.1/ EN 60601-1-2:2015/ A1:2021 IEC 61000-4-4 EN ISO 11608-4:2022
                          EMC - Surge:
                          a) Surge ±1 kV Line-to-Line ac mains
                          EC 60601-1-2 Edition 4.1/ EN 60601-1-2:2015/ A1:2021 IEC 61000-4-5 EN ISO 11608-4:2022
                          EMC - Conducted immunity disturbance by RF fields
                          a) 3 Vrms 150 kHz to 80 MHz (6 Vrms in ISM and amateur radio bands)
                          IEC 60601-1-2 Edition 4.1/ EN 60601-1-2:2015/ A1:2021 IEC 61000-4-6 EN ISO 11608-4:2022
                          EMC - Conducted emission
                          a) 150 kHz-30 MHz
                              120 V @ 60 Hz
                          Compliance levels according to CISPR11, Group1, Class B.
                          IEC 60601-1-2 Edition 4.1 EN 60601-1-2:2015/ A1:2021 CISPR 11/EN 55011 EN ISO 11608-4:2022
                          EMC - Voltage dips and interruptions:
                          a) <5% UT for 5 sec
                          b) <5% UT for 0.5 cycles
                          c) 70% UT for 25 cycles
                          d) 40% UT for 5 cycles
                          IEC 60601-1-2 Edition 4.1/ EN 60601-1-2:2015/ A1:2021 IEC 61000-4-11 EN ISO 11608-4:2022
                          EMC - RF Field Immunity to Proximity fields from Wireless communication equipment, Immunity at 0.3 m separation:
                          a) 27 V/m @ 380-390 MHz
                          b) 28 V/m @ 430-470 MHz
                          c) 9 V/m @ 704-787 MHz
                          d) 28 V/m @ 800-960 MHz
                          e) 28 V/m @ 1700-1990 MHz
                          f) 28 V/m @ 2400-2570 MHz
                          g) 9 V/m @ 5100-5800 MHz
                          IEC 60601-1-2 Edition 4.1/EN 60601-1-2:2015/ A1:2021 IEC 61000-4-39 EN ISO 11608- 4:2022
                          EMC - Immunity to proximity magnetic fields (9 kHz to 13.56 MHz):
                          a) 30 kHz - CW modulation - 8 A/m
                          b) 134.2 kHz - 2.1 kHz pulse modulation - 65 A/m
                          c) 13.56 MHz - 50 kHz pulse modulation - 7.5 A/m
                          IEC 60601-1-2 Edition 4.1/EN 60601-1-2:2015/ A1:2021 IEC 61000-4-39 EN ISO 11608- 4:2022
                          ESD immunity:
                          a) ± 8 kV contact
                          b) ± 2, 4, 8 and 15 kV air
                          IEC 60601-1-2 Edition 4.1/EN 60601-1-2:2015/ A1:2021 IEC 61000-4-2 EN ISO 11608- 4:2022

                          Technical Specification

                          SKYTROFA Auto-Injector
                          Lifetime

                          Expiration date

                          Image (Skytrofa 203)

                          Image (Skytrofa 203)

                          page 72.

                          Serial Number (SN)

                          Please refer to the bottom side of your auto-injector, marked after

                          Image (Skytrofa 203a)

                          Image (Skytrofa 203a)

                          .

                          Size7.09 × 1.46 × 1.06 in (180 × 37 × 27 mm).
                          Weight5.29 oz (150 g).
                          DisplayLight-emitting diodes (LED).
                          Power sourceMains charger: 100 to 240 V AC.
                          Power supply1 rechargeable internal Li-ion battery.
                          Full capacity charging time2 hours and 30 minutes. Charging time for 1 injection: 15 minutes.
                          Full capacity3 weeks with 1 injection per week.
                          Electromagnetic compatibilitySKYTROFA Auto-Injector meets the requirements of IEC / EN 60601-1- 2, 4-th Edition. Using SKYTROFA Auto-Injector in the immediate vicinity of microwave appliances may result in impaired functioning. Use and store SKYTROFA Auto-Injector outside such an environment.
                          Protection against electric shockType BF.
                          Dose accuracySKYTROFA Auto-Injector meets the requirements of ISO 11608-1:2022. Minimum 90% of the volume.
                          Needle Insertion DepthBased on needle length of 4 mm.
                          Ingress protectionIP22:
                          IP2X: Ingress protection of solid foreign objects, ≥ 12.5mm diameter. IPX2: Ingress protection of water with harmful effects, dripping (15% tilted). Both put together called IP22.
                          CableUSB to Micro-USB cable, 1m.
                          Bluetooth® VersionBLE v5.3 with frequency 2.4 GHz.
                          Software Bill of MaterialsThe off-the-shelf software components that are used in the SKYTROFA Auto-Injector can be found on: https://www.phillipsmedisize. com/sbom
                          Charger
                          ModelASSA54a-050100.
                          Input100-240V – 50-60Hz.
                          Output

                          5.0V

                          Image (Skytrofa 203b)

                          Image (Skytrofa 203b)

                          1.0A.

                          Use Conditions for SKYTROFA Auto-Injector
                          Operation temperature (with medicine) and recommended storage temperature in between uses59°F to 86°F (15°C to 30°C) (marking on device bottom).
                          Storage & Transportation temperature14°F to 104°F (-10°C to 40°C) (marking on device cover).
                          Charging temperature59°F to 86°F (15°C to 30°C).
                          Operation humidity15 to 90% relative humidity, non-condensing.
                          Storage & Transportation relative humidityUp to 93% relative humidity, non-condensing.
                          Atmospheric pressure10.15 psi to 15.37 psi (700 hPa to 1060 hPa).

                          Use Conditions for Cartridge with Medicine and Needles

                          The use conditions provided here are for the SKYTROFA Auto-Injector device. The use conditions for SKYTROFA Cartridges with medicine and needles may be different. To see the use conditions for cartridges with medicine and needles, please see the information provided with your medicine.

                          Waste

                          To protect natural resources and to promote material reuse, please separate packaging material from electronic, medicine, and sharp waste and recycle the material through your local recycling system.

                          Electronic waste: The auto-injector, including battery, must be returned to the manufacturer. Contact Ascendis Pharma Customer Support for instructions on how to return properly

                          Image (Skytrofa 204)

                          Image (Skytrofa 204)

                          back cover.

                          Charger and USB cable must be disposed of following local regulations for disposal of electronic waste.

                          Symbols

                          These symbols are found on the SKYTROFA Auto-Injector, the packaging, and the Instructions for Use.

                          Image (Skytrofa 205)

                          Image (Skytrofa 205)

                          Manufacturer.
                          Image (Skytrofa 206)

                          Image (Skytrofa 206)

                          Distributor.
                          Image (Skytrofa 207)

                          Image (Skytrofa 207)

                          Unique serial number of SKYTROFA Auto-Injector.
                          Image (Skytrofa 208)

                          Image (Skytrofa 208)

                          Model Number.
                          Image (Skytrofa 209)

                          Image (Skytrofa 209)

                          Manufacturer catalogue number for identification.
                          Image (Skytrofa 210)

                          Image (Skytrofa 210)

                          Manufacturer batch code for identification.
                          Image (Skytrofa 211)

                          Image (Skytrofa 211)

                          Medical Device.
                          Image (Skytrofa 212)

                          Image (Skytrofa 212)

                          Single patient Multiple use.
                          Image (Skytrofa 213)

                          Image (Skytrofa 213)

                          Expiration date.
                          Image (Skytrofa 214)

                          Image (Skytrofa 214)

                          Consult Instructions For Use.
                          Image (Skytrofa 215)

                          Image (Skytrofa 215)

                          Applied parts
                          SKYTROFA Auto-Injector is a type BF device and provides protection against electrical shock and electrical current leakage. Applied parts on the device are the green top, the housing, and the button.
                          Image (Skytrofa 216)

                          Image (Skytrofa 216)

                          Warning!
                          When this warning symbol is seen, safety instructions must be followed. Otherwise, serious safety hazardous situations and injuries may occur.
                          Image (Skytrofa 217)

                          Image (Skytrofa 217)

                          Precaution!
                          When this precaution symbol is seen, safety instructions must be followed. Otherwise, minor to moderate safety hazardous situations and injuries and potential damage to the auto-injector or other property may occur.
                          Rx onlyCaution: Federal law restricts this device for sale by or on the order of a physician.
                          Image (Skytrofa 218)

                          Image (Skytrofa 218)

                          Operation temperature.
                          Image (Skytrofa 219)

                          Image (Skytrofa 219)

                          Storage & Transportation temperature.
                          Image (Skytrofa 220)

                          Image (Skytrofa 220)

                          Keep dry.
                          Image (Skytrofa 221)

                          Image (Skytrofa 221)

                          If the auto-injector packaging has been damaged or unintentionally opened before the first use, contact customer support

                          Image (Skytrofa 222)

                          Image (Skytrofa 222)

                          back cover.

                          Image (Skytrofa 223)

                          Image (Skytrofa 223)

                          SKYTROFA Auto-Injector contains electrical and electronic components, including a battery that cannot be replaced, and must not be disposed of using standard waste collection.
                          Image (Skytrofa 224)

                          Image (Skytrofa 224)

                          SKYTROFA Auto-injector packaging is a non-corrugated fiberboard. Can be disposed of as paper.
                          Image (Skytrofa 225)

                          Image (Skytrofa 225)

                          SKYTROFA Auto-Injector has been tested and found to comply with the limits for a Class B digital device, according to part 15 of the FCC Rules.
                          Image (Skytrofa 226)

                          Image (Skytrofa 226)

                          Radio transmitter – Bluetooth® technology @2.4GHz using customized encrypted protocol – ClassB digital device.
                          Image (Skytrofa 227)

                          Image (Skytrofa 227)

                          DC (Direct Current).
                          Image (Skytrofa 228)

                          Image (Skytrofa 228)

                          Bluetooth® technology
                          The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Ascendis Pharma is under license. Other trademarks and trade names are those of their respective owners.
                          Image (Skytrofa 229)

                          Image (Skytrofa 229)

                          Pairing key.

                          Image (Skytrofa 230)

                          Image (Skytrofa 230)

                          The Unique Device Identifier (UDI) that appears on the carton is shown by a barcode and human readable format:
                          (01) Device Identifier
                          (10) Batch Number
                          (17) Expiry date in YYMMDD format
                          (21) Serial Number

                          FCC Class B Notice

                          It is not allowed to modify the SKYTROFA Auto- Injector. Modifications may void the authority granted to the user by the FCC to operate this equipment.

                          This device complies with Part 15 of the FCC Rules. Operation is subject to the following two conditions:

                          • This device may not cause harmful interference.
                          • This device must accept any interference received, including interference that may cause undesired operation.
                          • Note: This equipment has been tested and found to comply with the limits for a Class B digital device, pursuant to Part 15 of the FCC Rules.

                            These limits are designed to provide reasonable protection against harmful interference in a residential installation. This equipment generates, uses and can radiate radio frequency energy and, if not installed and used in accordance with the instructions, may cause harmful interference to radio communications. However, there is no guarantee that interference will not occur in a particular installation. If this equipment does cause harmful interference to radio or television reception, which can be determined by turning the equipment off and on, the user is encouraged to try to correct the interference by one or more of the following measures:

                            • –Reorient or relocate the receiving antenna.
                            • –Increase the separation between the equipment and receiver.
                            • –Connect the equipment into an outlet on a circuit different from that to which the receiver is connected.
                            • –Consult the dealer or an experienced radio/television technician for help.
                            • Warranty and Disclaimer

                              Warranty

                              After the expiration date, your SKYTROFA Auto-Injector must be replaced. Please contact a healthcare provider or Ascendis Pharma Customer Support to receive a new auto-injector. For contact information

                              Image (Skytrofa 231)

                              Image (Skytrofa 231)

                              back cover.

                              The expiration date is located at the bottom of the auto-injector and is indicated by year (YYYY), month (MM), and date (DD), printed as YYYY-MM-DD.

                              Disclaimer

                              The correct application of SKYTROFA according to the information provided with your medicine remains your responsibility.

                              Ascendis Pharma Endocrinology Inc. shall have no liability for incidental or consequential damages.

                              We reserve the right to modify technical specifications and documentation.

                              Patent Information

                              www.ascendispharma.us/products/patents

                              Parts Overview

                              Image (Skytrofa 232)

                              Image (Skytrofa 232)

Quick Reference Guide

Skytrofa® Auto-Injector

Image (Skytrofa 233)

Image (Skytrofa 233)


For SKYTROFA cartridges

Single-patient use
Image (Skytrofa 234)

Image (Skytrofa 234)

Image (Skytrofa 235)

Image (Skytrofa 235)

This is your
Quick Reference Guide

  • Read your Instructions for Use for full instructions before using this Quick Reference Guide.
  • For training video, go to www.skytrofa.com
  • If you are unsure about your dose, contact your healthcare provider.
  • Image (Skytrofa 236a)

    Image (Skytrofa 236a)

    # 02 2026-07-02 8020100530_08

    Parts overview

    Image (Skytrofa 240)

    Image (Skytrofa 240)

    Image (Skytrofa 241)

    Image (Skytrofa 241)


    Constant green
    Image (Skytrofa 242)

    Image (Skytrofa 242)

    Battery is fully charged
    Image (Skytrofa 243)

    Image (Skytrofa 243)

    The SKYTROFA
    Auto-Injector is ready to use

    Image (Skytrofa 244)

    Image (Skytrofa 244)


    Flashing green
    Image (Skytrofa 245)

    Image (Skytrofa 245)

    At least 1 injection remaining, but charging recommended after use

    Image (Skytrofa 246)

    Image (Skytrofa 246)


    Flashing orange
    Image (Skytrofa 247)

    Image (Skytrofa 247)

    Battery needs charging

    Quick troubleshooting

    For all troubleshooting cases and details, see Instructions for Use (IFU)

    Image (Skytrofa 248)

    Image (Skytrofa 248)

    IFU page 52

    Charging required (Step 2)

    Image (Skytrofa 249)

    Image (Skytrofa 249)

    IFU page 57

    Image (Skytrofa 250)

    Image (Skytrofa 250)

    If the battery level is low:

    Image (Skytrofa 251)

    Image (Skytrofa 251)

    You will see a flashing orange battery icon.
    Do this: Insert charging cable into the SKYTROFA Auto-Injector at rear lower side and connect to a power outlet.

    SKYTROFA Auto-Injector not upright (Step 4 and 6.1)

    Image (Skytrofa 252)

    Image (Skytrofa 252)

    IFU page 54

    Image (Skytrofa 253)

    Image (Skytrofa 253)

    If the SKYTROFA Auto-Injector is not in an upright position during mixing and air removal:

    Image (Skytrofa 254)

    Image (Skytrofa 254)

    You will hear a repeating notification sound. Mixing icon will flash slowly and progress bar will freeze.
    Do this: Place the SKYTROFA Auto-Injector in an upright position and the mixing or air removal will continue.

    Skin contact lost (Step 9)

    Image (Skytrofa 255)

    Image (Skytrofa 255)

    IFU page 55

    Image (Skytrofa 256)

    Image (Skytrofa 256)

    If the green top is removed from skin before the injection is complete:

    Image (Skytrofa 257)

    Image (Skytrofa 257)

    You will hear a repeating notification sound. Check mark icon will flash slowly and progress bar will freeze.
    Do this: Press green top against skin and the injection will continue.

    Prepare

    1 Check and assemble cartridge and needle

    1.11.21.3
    Check expiration date and cartridge dose on cartridge pack. If refrigerated, allow 15 minutes to reach room temperature.

    Image (Skytrofa 258)

    Image (Skytrofa 258)

    Image (Skytrofa 259)

    Image (Skytrofa 259)

    Screw needle straight and tightly on cartridge. Do not remove needle cover.

    Image (Skytrofa 261)

    Image (Skytrofa 261)

    Remove paper from needle.

    Image (Skytrofa 260)

    Image (Skytrofa 260)

    2 Turn on the auto-injector

    Image (Skytrofa 262)

    Image (Skytrofa 262)

    Image (Skytrofa 263)

    Image (Skytrofa 263)

    (You will hear 2 loud beeps. Battery icon

    Image (Skytrofa 264)

    Image (Skytrofa 264)

    will light up and green top will start flashing)

    3 Insert cartridge with attached needle

    Image (Skytrofa 265)

    Image (Skytrofa 265)

    3.1

    Image (Skytrofa 266)

    Image (Skytrofa 266)

    3.2

    Image (Skytrofa 267)

    Image (Skytrofa 267)

    3.3

    Mix

    4 Wait while mixing

    Wait 4 to 8 minutes for the auto-injector to mix medicine.
    Watch progress bar gradually light up.
    Image (Skytrofa 268)

    Image (Skytrofa 268)

    Image (Skytrofa 269)

    Image (Skytrofa 269)


    Wait until you hear 2 loud beeps and the entire progress bar flashes.

    If your auto-injector turns off automatically read Instructions for Use

    Image (Skytrofa 270)

    Image (Skytrofa 270)

    IFU page 60.

    5 Turn the auto-injector up and down

    Image (Skytrofa 271)

    Image (Skytrofa 271)

    Turn the auto-injector up and down, listening for a tick sound each up and down cycle to make sure the turns are correct. Turn up and down correctly 5 to 10 times until you hear 2 loud beeps and the whole progress bar, except the top element, lights up. Do not press the green button.

    If you see a flashing orange mixing icon read

    Image (Skytrofa 272)

    Image (Skytrofa 272)

    IFU page 58.

    6 Finish mixing

    6.1

    Image (Skytrofa 274)

    Image (Skytrofa 274)

    6.2
    Keep the auto-injector upright on a flat surface until you hear 2 loud beeps and the entire progress bar lights up.

    Image (Skytrofa 273)

    Image (Skytrofa 273)

    Inject

    7 Check mixed medicine

    Image (Skytrofa 275)

    Image (Skytrofa 275)

    8 Prepare for injection

    8.18.28.3

    Choose an injection site:
    Stomach (abdomen), thighs, or buttocks.
    Change the injection site for every injection.

    Image (Skytrofa 276)

    Image (Skytrofa 276)

    Make sure your hands are clean using soap and water or hand sanitizer.

    Image (Skytrofa 277)

    Image (Skytrofa 277)

    Clean injection site with alcohol wipe. Do not inject through clothes.

    Image (Skytrofa 278)

    Image (Skytrofa 278)

    9 Inject medicine

    9.19.2
    Image (Skytrofa 279)

    Image (Skytrofa 279)

    Image (Skytrofa 280)

    Image (Skytrofa 280)

    After injection

    10 Remove cartridge

    10.110.2
    Image (Skytrofa 281)

    Image (Skytrofa 281)

    Image (Skytrofa 282)

    Image (Skytrofa 282)

    11 Check cartridge and throw away

    Image (Skytrofa 283)

    Image (Skytrofa 283)

    12 Store the auto-injector

    Image (Skytrofa 284)

    Image (Skytrofa 284)

Principal Display Panel - 3 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

3 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127883

NDC 73362-003-01

GTIN: 00373362003010

Principal Display Panel (3 mg Cartridge Blister Pack Carton)

Principal Display Panel (3 mg Cartridge Blister Pack Carton)

Principal Display Panel - 3.6 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

3.6 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127889

NDC 73362-004-01

GTIN: 00373362004017

Principal Display Panel (3.6 mg Cartridge Blister Pack Carton)

Principal Display Panel (3.6 mg Cartridge Blister Pack Carton)

Principal Display Panel - 4.3 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

4.3 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

130972

NDC 73362-005-01

GTIN: 00373362005014

Principal Display Panel (4.3 mg Cartridge Blister Pack Carton)

Principal Display Panel (4.3 mg Cartridge Blister Pack Carton)

Principal Display Panel - 5.2 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

5.2 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127882

NDC 73362-006-01

GTIN: 00373362006011

Principal Display Panel (5.2 mg Cartridge Blister Pack Carton)

Principal Display Panel (5.2 mg Cartridge Blister Pack Carton)

Principal Display Panel - 6.3 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

6.3 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

130973

NDC 73362-007-01

GTIN: 00373362007018

Principal Display Panel (6.3 mg Cartridge Blister Pack Carton)

Principal Display Panel (6.3 mg Cartridge Blister Pack Carton)

Principal Display Panel - 7.6 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

7.6 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127886

NDC 73362-008-01

GTIN: 00373362008015

Principal Display Panel (7.6 mg Cartridge Blister Pack Carton)

Principal Display Panel (7.6 mg Cartridge Blister Pack Carton)

Principal Display Panel - 9.1 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

9.1 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127885

NDC 73362-009-01

GTIN: 007373362009012

Principal Display Panel (9.1 mg Cartridge Blister Pack Carton)

Principal Display Panel (9.1 mg Cartridge Blister Pack Carton)

Principal Display Panel - 11 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

11 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127884

NDC 73362-010-01

GTIN: 00373362010018

Principal Display Panel (11 mg Cartridge Blister Pack Carton)

Principal Display Panel (11 mg Cartridge Blister Pack Carton)

Principal Display Panel - 13.3 Mg Cartridge Blister Pack Carton

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

13.3 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127881

NDC 73362-011-01

GTIN: 00373362011015

Principal Display Panel (13.3 mg Cartridge Blister Pack Carton)

Principal Display Panel (13.3 mg Cartridge Blister Pack Carton)

Principal Display Panel - 0.7 Mg Cartridge Blister Pack Box

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

0.7 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127880

NDC 73362-012-01

GTIN: 00373362012012

LOT NNNNNNNN

Expiration YYYY-MM

SN NNNNNNNNNNNN

Principal Display Panel (0.7 mg Cartridge Blister Pack Box)

Principal Display Panel (0.7 mg Cartridge Blister Pack Box)

Principal Display Panel - 1.4 Mg Cartridge Blister Pack Box

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

1.4 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127879

NDC 73362-013-01

GTIN: 00373362013019

LOT NNNNNNNN

Expiration YYYY-MM

SN NNNNNNNNNNNN

Principal Display Panel (1.4 mg Cartridge Blister Pack Box)

Principal Display Panel (1.4 mg Cartridge Blister Pack Box)

Principal Display Panel - 1.8 Mg Cartridge Blister Pack Box

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

1.8 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127878

NDC 73362-014-01

GTIN: 00373362014016

LOT NNNNNNNN

Expiration YYYY-MM

SN NNNNNNNNNNNN

Principal Display Panel (1.8 mg Cartridge Blister Pack Box)

Principal Display Panel (1.8 mg Cartridge Blister Pack Box)

Principal Display Panel - 2.1 Mg Cartridge Blister Pack Box

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

2.1 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127877

NDC 73362-015-01

GTIN: 00373362015013

LOT NNNNNNNN

Expiration YYYY-MM

SN NNNNNNNNNNNN

Principal Display Panel (2.1 mg Cartridge Blister Pack Box)

Principal Display Panel (2.1 mg Cartridge Blister Pack Box)

Principal Display Panel - 2.5 Mg Cartridge Blister Pack Box

Skytrofa®
(lonapegsomatropin-tcgd)
for injection

2.5 mg

Box with:
4 single-dose cartridges and
6 sterile injection needles

OPEN HERE

127876

NDC 73362-016-01

GTIN: 00373362016010

LOT NNNNNNNN

Expiration YYYY-MM

SN NNNNNNNNNNNN

Principal Display Panel (2.5 mg Cartridge Blister Pack Box)

Principal Display Panel (2.5 mg Cartridge Blister Pack Box)

* Please review the disclaimer below.